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ABSTRACT OF THE DISSERTATION 
 
RISK FACTORS AND ASSOCIATIONS FOR HEPATITIS C INFECTION AMONG 
HISPANIC/LATINO INTRAVENOUS DRUG USERS IN MIAMI-DADE COUNTY, 
FLORIDA 
by 
Arturo E. Rodríguez 
Florida International University, 2012 
Miami, Florida 
Professor Jessy G. Dévieux, Major Professor 
Hepatitis C infection (HCV) continues to disproportionately affect Hispanics/Latinos in 
the United States. Hispanic/Latino intravenous drug users (IDUs), because of their risky 
injection and sexual behaviors, are prone to HCV infection and rapid transmission of the 
virus to others via several routes. With a prevalence rate of approximately 75% among 
IDUs, it is imperative that transmission of HCV be prevented in this population. This 
study aims to examine the associations between demographic, injection and sexual risk 
factors to HCV infection in a group Hispanic/Latino IDUs in Miami-Dade County, 
Florida. Preliminary unadjusted results in this sample reveal that age (OR=4.592, 
p=0.004), weekly injection (OR=5.171, p=0.000), daily injection frequency (OR=3.856, 
p=0.000) and use of a dirty needle (OR=2.320, p= 0.006) were all significantly associated 
with HCV infection. Being born outside the U.S. was significantly negatively associated 
with HCV infection (OR=0.349, p=0.004). Additionally, having two or more sex partners 
in the past three months (OR=0.472, p=0.014) was negatively associated with HCV 
infection. After adjusting for all other variables, older age (AOR=7.470, p=0.006), 
  vii
weekly injection (AOR=3.238, p=0.007) and daily injection frequency (AOR=2.625, 
p=0.010) were all significantly associated with HCV infection. Being born outside the 
U.S. (AOR=0.369, p=0.019) was a significant protective factor for HCV infection, along 
with having two or more sex partners in the past three months (AOR=0.481, p=0.037). 
When analyzing the significant variables in a backward regression model, having 2 or 
more sex partners in the past three months was not significant at the p<0.05 level, 
meaning that it could be a confounder in the final model. Utilizing these results, a 
targeted intervention aimed at reducing HCV infection in the Hispanic/Latino IDU 
population is proposed, utilizing individual risk factors that were found to be significantly 
associated with HCV infection. The intervention is tailored around 1) assessing the 
individual’s readiness to change the selected behavior, and 2) systematic activities aimed 
at moving individuals from one stage to another, with established outcomes needed to 
successfully move to another stage. If significant risk factors could be readily identified 
and modified, taking into consideration the unique differences between people in 
different Hispanic/Latino groups, as well as protective factors, an effective prevention 
program that targets these behaviors could be developed. 
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CHAPTER I 
INTRODUCTION 
 Hepatitis C (HCV) infects approximately 4 million Americans today and has 
become a major public health concern in the past decade (Centers for Disease Control 
and Prevention [CDC], 2011; CDC, 2008a; Birkhead et al., 2007). Most people who are 
chronically infected are unaware of their infection because they generally do not show 
signs of being clinically ill (CDC, 1998). HCV related mortality is likely to surpass 
deaths related to human immunodeficiency virus (HIV) and to triple by the year 2030 if 
current screening and treatment efforts for HCV infection are not improved (Deuffic-
Burban, Poynard, Sulkowski, & Wong, 2007). The economic impact of chronic HCV 
infection in the United States (U.S.) is projected to exceed $1 billion per year in direct 
medical expenses between 2010 and 2019 (Wong, McQuillan, Hutchinson, & Poynard, 
2000). Clearly, HCV continues to be an important public health concern for the future as 
well as a significant economic burden on the health care system. 
 Reducing the number of HCV infections and impact of HCV-related disease in the 
United States requires implementation of primary prevention activities to reduce the risk 
for contracting HCV infection and secondary prevention activities to reduce the risk for 
liver and other chronic diseases in HCV-infected persons (CDC, 1998). Due to the 
common risk factors with HIV, the initial recommendation for HCV containment was 
that comprehensive programs be developed and implemented. These programs would be 
aimed at conducting surveillance, preventing new cases, ensuring early detection, 
counseling infected individuals and providing care, just like the programs currently in 
place for HIV (Birkhead et al., 2007). Unfortunately, these HCV prevention 
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interventions, modeled after current HIV interventions, are simply not working (Crofts, 
Aitken, & Kaldor, 1999; Vlahov, Fuller, Ompad, Galea, & Des Jarlais, 2004; European 
Centre for Disease Control and Prevention, 2011).  
 Interventions that currently prevent HIV may not prevent HCV infection mainly 
due to HCV’s high prevalence. HCV prevalence is 3.2 million in the U.S. vs. HIV 
prevalence of 1.2 million (Birkhead et al, 2007; CDC, 2008). Several HCV prevention 
programs are available, however their effectiveness has not been tested, and as of today, 
targeted, comprehensive HCV prevention strategies are still needed (Crofts, Caruana, 
Bowden, & Kerger, 2000; Hagan & Des Jarlais, 2000; Edlin & Carden, 2006; Birkhead et 
al., 2007). Unlike HIV, HCV also lacks a large, active advocacy group, and resources are 
yet to be made available in order to sustain a viable public health effort (Edlin & Carden, 
2006; USDHHS, 2001). Finally, while the majority of HIV behavioral programs to date 
intervene at the individual level, most HCV interventions have yet to utilize that 
methodology (Herbst et al., 2007).  
Risky injection practices are by far the most significant risk factors for HCV 
(Matheï, Robaeys, Van Damme, Buntinx, & Verrando, 2004). In addition to sharing 
needles, there is growing evidence that HCV infection may also be possible through the 
sharing of other injection materials such as spoons (cookers), filters, and rinse water 
(Matheï et al., 2004). 
Sexual behavior is a relatively understudied risk factor for HCV, but has been 
found to be associated with HCV infection as well (Burt et al., 2007). A history of sex 
work, prior history of sexually transmitted infection (STI), high-risk sexual behaviors 
among men who have sex with men (MSM), and a history of multiple sexual partners 
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have been associated with HCV infection (Burt et al., 2007; Matheï et al., 2004; van de 
Laar et al., 2007; Armstrong, Wasley, Simard, McQuillan, Kuhnert, & Alter, 2006; 
Lavanchy, 2002; Wu et al., 2006).  
Demographic factors such as race and age as well as lower educational attainment 
have also been associated with HCV infection (Burt et al., 2007; Operskalski et al., 
2008). While to date there are no studies that specifically examine age and gender risks of 
HCV infection in Hispanic/Latino groups, studies in Montreal show that younger age 
(mean was 32 years) and male gender (70%) were strong predictors of injection 
equipment sharing, which is hypothesized to be a strong predictor of HCV infection (De 
et al., 2009). Studies among intravenous drug users (IDUs) in New York City showed a 
mean HCV prevalence of 47% in men (versus 44% in women) and a mean age of 26.1 
years (Hagan et al. 2007). Only one study showed women were more likely to test 
positive for HCV (42% versus 27% in men; Neaigus et al., 2007). It is important to note 
that the latter study’s participants were 81% white, non-Hispanic. 
Why do Hispanics/Latinos present a unique problem with HCV? 
Recently arrived Hispanics/Latinos to the U.S. bring with them their own 
customs, which have been found to keep this group healthier than U.S. born 
Hispanics/Latinos, despite a lower socioeconomic status (Smith, 2006). As their length of 
residence in the U.S. increases, the protective effect of their original customs wanes 
because they adopt more unhealthy behaviors in their new environment (Abraido-Lanza, 
Chao, & Flórez, 2005). Length of residence in the U.S. among the Hispanic/Latino 
population has been correlated with higher fat intake and lower fruit and vegetable 
consumption, higher risk of obesity, and increased risk of psychiatric and substance use 
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disorders, including adoption of HCV risk behaviors (Neuhouser, Thompson, Coronado, 
& Solomon, 2004; Gordon-Larsen, Harris, Ward, & Popkin, 2003; Trooskin et al., 2010). 
Minority populations have been disproportionately affected by HCV (Trooskin et 
al., 2010). This disparity has been primarily documented in Mexican-Americans (2.1% 
vs. 1.5% in non-Hispanic Whites) in the U. S. (Rodriguez-Torres, 2008; Armstrong et al., 
2006). Mexican-Americans comprise approximately 67% of the Hispanic/Latino 
population in the U. S. while the rest of the Hispanic/Latino population is comprised of 
numerous groups from the Caribbean, and Central and South America. Specific incidence 
and prevalence rates for Hispanic/Latino groups other than Mexican Americans are not 
available in the literature (U.S. Census Bureau, 2011; Trooskin et al., 2010; Rawls & 
Vega, 2005). 
The natural progression of HCV among Hispanics/Latinos is not well defined 
(Rawls & Vega, 2005). Hispanics/Latinos with HCV have been shown to have higher 
liver enzymes (alanine transaminase, aspartate transaminase, and bilirubin) as compared 
to other racial/ethnic groups (Jamal et al., 1999; Celona, Yu, Prakash, Kuo, & Bonacini, 
2004). HCV infected Hispanics/Latinos have also been shown to progress faster with 
liver fibrosis than African Americans or whites (Bonacini, Groshen, Yu, Govinarajan, & 
Lindsay, 2001). Data are not available in the literature regarding response to therapy 
among Hispanics/Latinos (Trooskin, 2010). 
Lack of access to healthcare has also been shown to increase HCV prevalence 
among Hispanic/Latino IDUs. Research has shown that, in general, minorities are less 
likely to receive medical treatment than their white counterparts (Epstein et al., 2000, 
Fiscella et al., 2000). This disparity has been attributed to provider racism as well as 
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patient distrust of medical research (King, 2003). For example, many patients who 
actively inject drugs are deemed “ineligible for treatment” by the healthcare provider 
(Grebely, Genoway, Raffa, & Dhadwal, 2008). IDU patients may not follow their 
physicians’ advice, are less likely to fully and truthfully disclose their IDU use and 
associated behaviors, and/or fail to keep their appointments (Kresina et al., 2005). 
Healthcare providers caring for drug users often experience these behaviors as frustrating 
and are more likely to refer the patient to addiction specialists or a drug treatment facility, 
unintentionally denying caring for IDUs (Kresina et al., 2005). 
Research has also demonstrated that health beliefs differ based on race and 
ethnicity (Talavera, Elder, & Velasquez, 1997). Beliefs about health may influence 
whether a participant complies with physician recommendations as well as the utilization 
of routine health screenings, and may also lead to avoiding participation in research 
interventions, particularly for a disease that was likely acquired through illegal activity 
(Nelson, Geiger, & Mangione, 2002). Only one study to date has demonstrated that HCV 
knowledge varies between races and that overall, HCV knowledge in minorities is poor 
(Buffington, Damon, Moyer, & Culver, 2000). Differences in knowledge about disease 
processes overall may also differ within different Hispanic/Latino subpopulations (Loue, 
Cooper, & Fiedler, 2003). This finding could be the case for HCV as well. Research has 
found that knowledge about a particular disease may depend on the level of acculturation 
of the patient (Harmon, Castro, & Coe, 1996). This research underscores the many 
barriers that Hispanics/Latinos face when it comes to overall healthcare and HCV 
infection in particular. 
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Given the evidence at hand: 1) high HCV prevalence in the IDU population, 2) 
disproportionate effect of HCV infection in Hispanics/Latinos, 3) little knowledge of 
Hispanic/Latino groups, and 4) currently no extant comprehensive and effective HCV 
prevention strategy/program, this study will lay the foundation for understanding the risk 
factors that affect Hispanics/Latinos (with emphasis on groups other than Mexicans) with 
regards to HCV infection. The main purpose of this study is to identify risk factors for 
HCV infection and identify the strength of association between the identified HCV risk 
factors and HCV infection in a group of Hispanic/Latino IDUs in Miami-Dade County, 
Florida. Identification of these behaviors may serve as a basis for targeted interventions 
to help reduce the prevalence rate of HCV infection in these Hispanic/Latino groups of 
IDUs. By identifying the circumstances and characteristics that are associated with 
infection, progress towards HCV infection prevention will be made (Hagan et al., 2007). 
Research Aims, Questions and Hypotheses 
 In order to address the various issues presented in this proposal, the following aims, 
research questions, and hypotheses have been formulated: 
Research aim #1: To identify the risk factors for HCV infection in Hispanic/Latino 
intravenous drug users. 
Research aim #2:  To calculate the strength of association between the identified risk 
factors and HCV infection in Hispanic/Latino IDUs. 
 Research aims #1 and #2 will be achieved via the following research 
questions/hypotheses: 
• Research question #1: Are demographic factors associated with HCV infection in 
Hispanic/Latino IDUs in Miami-Dade County, Florida? 
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• Hypothesis #1a: In comparison with HCV negative individuals, HCV positive 
individuals will be more likely to be unemployed (employment, income) as well as 
be less likely to be educated (education level) and have familial stability (marital 
status, residency). 
• Hypothesis #1b: In comparison with HCV negative individuals, HCV positive 
individuals will be older (age) and will be more likely to be male (gender). 
• Hypothesis #1c: In comparison with HCV negative individuals, HCV positive 
individuals will be more likely to have resided in the U.S. for a longer period of 
time (number of years in the U.S.) and be born in the U.S. (born in the U.S.). 
• Research question #2: Is there a relationship between sexual behaviors and HCV 
infection in Hispanic/Latino IDUs? 
• Hypothesis #2: HCV positive individuals will be more likely to engage in high-
risk sexual behaviors than HCV negative individuals as measured by sexual 
history (age at first sexual encounter) and number of sex partners (number of sex 
partners in last 3 months, number of sex partners in a lifetime). 
• Research question #3: Is there a relationship between different drug use behaviors and 
HCV infection in different Hispanic/Latino IDUs? 
• Hypothesis #3a: HCV positive individuals will be more likely to engage in high-
risk injection behaviors than HCV negative individuals, as measured by 
utilization of shared injection paraphernalia (cooker, cotton, rinse water, syringes) 
and injection frequency (weekly injection frequency, daily injection frequency).  
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• Hypothesis #3b: HCV positive individuals will be more likely to have a larger 
percentage of IDUs in their personal network than HCV negative individuals 
(IDUs in network). 
Research aim #3: To utilize the knowledge gained from the study and develop a targeted, 
theoretically based HCV prevention program for Hispanic/Latino IDUs in Miami-Dade 
County, Florida aimed at specifically targeting individuals in any stage of behavior 
change and systematically moving them to a new stage via a series of activities designed 
to change participants’ health behavior. 
Research aim # 3 will be achieved by synthesizing the knowledge gained from the 
study. Utilizing the transtheoretical model (TTM) as a theoretical basis, a comprehensive, 
tailored HCV prevention intervention will be developed. The main goals of this 
intervention will be the primary prevention and reduction of transmission from HCV-
infected individuals to non-infected individuals in the Hispanic/Latino IDU community. 
Theoretical basis 
  The TTM is a process-oriented paradigm that views intentional behavior 
changes as a progression of several stages (Prochaska & DiClemente, 2005). The TTM 
hypothesizes that individuals move through a series of five stages (pre contemplation, 
contemplation, preparation, action, maintenance) in the adoption of healthy behaviors or 
cessation of unhealthy ones (Prochaska et al., 2008). The five stages are summarized 
below with their specific applications to Hispanic IDUs and the risk factor “use new 
needles” used as an example. 
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• Pre contemplation. The participant is unaware that change is needed or does not see 
the problem (The participant has no intention of using new needles at every injection 
session in the next six months). 
• Contemplation. The participant recognizes the need for behavior change, but is not 
confident on his or her ability to do so (There is an intention to use new needles at 
every injection session in the next six months). 
• Preparation. The participant is close to making a behavior change but may need new 
skills for making change (Intend to use new needles in the next 30 days or already 
using new needles but not consistently). 
• Action. Behavior change has been accomplished (New needles used at every injection 
session but for less than six months). 
• Maintenance. Behavior change has continued for an extended period of time 
(Consistent new needle use at every injection session for at least six months or more). 
 The TTM has also been used for a variety of health behaviors, including readiness 
to change blood-borne virus transmission behaviors (Ko, 2010; Gasiorowicz et al., 2005). 
An often-cited advantage of the TTM is that it very flexible and can be applied to a range 
of situations (Armitage, 2009). The TTM, along with information gained from the data 
analysis from the current study will be used to develop an intervention aimed at reducing 
HCV infection in Hispanic/Latino IDU’s. The TTM makes no assumption about how 
ready an individual is to change and recognizes that different individuals will be in 
different stages and therefore appropriate interventions must be developed to reflect this 
individuality (Velicer, et al. 2004). It is also acknowledged that not one single path of 
change process can be applied to every health behavior (Hasler et al., 2003). 
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Research conducted on behavioral change using the TTM show that interventions 
become more effective when tailored to the current stage of change of the individual 
(Levesque, Prochaska, & Prochaska, 1999). By using more cognitive-affective processes 
(person, situation and their interaction) throughout each stage of change, an 
educator/counselor cultivates motivation; if, however, the educator uses more behavioral 
processes of change he or she may be met with more resistance (Levesque, et al., 1999; 
Rosen, 2000). Other studies show that a combination of cognitive-affective and 
behavioral interventions is most effective and varies by health condition (Rosen, 2004). 
Since there is little agreement, therefore on intervention strategies with this population, a 
pilot stage of the intervention is proposed (prior to it being used in the general 
population) in which the use of both cognitive-affective and behavioral interventions will 
be measured and carefully calibrated to maximize results. 
In a study of 322 African American male street addicts in Texas, Stephens et al. 
(1993) reported that after counseling delivered by a professionally trained health 
educator, the percentage of participants who reported injecting frequently decreased from 
92% to 71% at a 3-month follow up. In addition, it was also reported that needle-sharing 
behavior in this particular group declined from 67% to 24% of respondents (Stephens, et 
al., 1993). The proposed study will have counseling sessions delivered by trained 
outreach educators to a group of Hispanic/Latino IDU’s (analogous to the African 
American IDUs in the Stephens et al. article). 
 Des Jarlais et al. (1992) studied the effects of teaching safe injection practices to a 
group of heroin users (both sniffers and injectors) in New York in order to determine if, 
1) the rate of users transitioning to injecting heroin from sniffing would decrease, and 2) 
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the rate of injection risk behaviors were reduced in already injecting users. At a 9-month 
follow up, there was a significantly lower level of injection in the groups. After the 
education intervention, 15% of follow up respondents were injecting frequently versus 
33% in a control group (Des Jarlais, et al., 1992). The proposed intervention will build on 
this finding by utilizing the safer injection practices and “AIDS 101” curriculum as 
utilized by Des Jarlais and colleagues. 
 Utilizing the few extant examples of successful individual and group level 
interventions for IDUs, the proposed intervention builds on those by introducing 
interventions that are culturally targeted to the Hispanic/Latino IDU. 
Summary 
 The purpose of this dissertation is to determine whether known HCV risk factors 
in the overall IDU population, such as demographic, injection, and sexual risk factors, 
differ not only from the overall IDU population, but also within Hispanic/Latino 
populations. In addition, this dissertation lays the groundwork and proposes a community 
based intervention program aimed at reducing HCV infection in Hispanic/Latino 
populations based on any differences in risk factors learned from the initial part of the 
study. The remaining sections of this dissertation will, 1) examine the factors related to 
HCV transmission that have been explored in the literature, 2) determine whether there 
are any statistically significant risk factors (demographic, injection and sexual) within the 
Hispanic/Latino population, and using that information, 3) propose a targeted, 
theoretically based HCV prevention intervention. 
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CHAPTER II 
LITERATURE REVIEW 
HCV Transmission 
Hepatitis C is one of six known hepatitis viruses (Chen & Morgan, 2006; CDC, 
2008). It was initially discovered in 1989 when it was isolated from an individual with 
non-A, non-B hepatitis (Chen & Morgan, 2006). This finding led to the discovery that 
approximately 90% of all non-A, non-B cases were HCV infections (Chen and Morgan, 
2006). There are six identified HCV genotypes and over 100 subtypes (Chen & Morgan, 
2006; Chevaliez & Pawlotsky, 2007, American Public Health Association [APHA], 
2008). Approximately 70% of HCV cases in the U. S. are genotype 1, the majority of 
those being subtype 1a (CDC, 1998).  
The evidence for transmission of HCV via pathways other than IDU remains 
unclear (Division of Viral Hepatitis and National Center for HIV/AIDS, Viral Hepatitis, 
STD, and TB Prevention, 2009). Blood transfusions accounted for a large proportion of 
HCV infections in the late 1980’s (CDC, 2008). In the 1990’s, HCV infection from blood 
transfusions was virtually non-existent, although the risk was never zero (CDC, 2008). 
The risk was so low that the Center for Disease Control’s (CDC) sentinel counties in their 
viral hepatitis surveillance system were unable to detect any cases (CDC, 2008). Today, 
however, the CDC considers HCV infection from blood transmissions as “intermediate 
risk” and recommends testing for anybody who has received a blood transfusion (CDC, 
2008a). 
The most efficient means of transmission of HCV occurs through percutaneous 
exposure to HCV infected blood (APHA, 2008). Other documented means of 
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transmission include sharing of contaminated needles or equipment for drug use, receipt 
of infected blood, blood products and organs, vertical transmission, needle sticks in 
health care settings, sexual contact with an HCV infected individual, sharing of personal 
items (such as razors or toothbrushes), invasive health care procedures, tattooing, body 
piercing and acupuncture (Alter, 1997; Burt et al., 2007; CDC, 2008; CDC, 1998; 
Rhoads, 2003; Solomon et al., 2011; Hand & Vazquez, 2005). IDU however, is by far the 
most reliable factor for HCV infection (Hagan et al, 2011). HCV is identified as the most 
common infection affecting IDUs, and injection drug use has been identified as the main 
mode of transmission (McMahon, Pouget, & Tortu, 2007). 
Epidemiology of HCV infection 
The National Center for Health Statistics (NCHS) at the CDC estimated that 
between 1999 and 2002, 1.6% of the non-institutionalized, civilian U.S. residents ages six 
and older were HCV positive (Armstrong et al., 2006). During the same time period, 
79.7% of these were considered to be chronically infected (Armstrong et al., 2006). This 
equates to a prevalence of approximately 1.3% or 3.2 million individuals aged six or 
older in the U.S. living with chronic HCV (Davis et al., 2003). Overall, the demographic 
group with the highest anti-HCV antibody prevalence was non-Hispanic black males 
between the ages of 40 and 49 (CDC, 2008). Acute HCV infection, however, is primarily 
found among persons aged 20–49 years, and males have a slightly higher incidence rate 
(Deacon et al., 2011).  
HCV has had a pattern of disproportionate impact among Hispanics/Latinos, but 
statistics are hard to find for a number of reasons (Birkhead et al., 2007). First, 
Hispanics/Latinos are chronically underrepresented in clinical trials (Fleckenstein, 2004). 
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Part of the problem lies with the different terms Hispanic vs. Latino. These two terms are 
often utilized interchangeably in the literature, and leads to the impression that any 
person who speaks Spanish may be grouped into one homogeneous group with the same 
customs, beliefs and risk factors for any particular disease (Blessman, 2008; Zambrana & 
Carter-Pokras, 2010). There are many groups within the larger Hispanic/Latino group in 
the U.S., each with their own cultural background and health beliefs. As a consequence, 
each subgroup has its own risk factors for any health outcome. This un-acknowledged 
diversity leads to difficulty in searching the literature, as ethnic groups are not well 
defined in research (Blessman, 2008). Second, only approximately 75-85% of HCV cases 
are actually reported. This is probably due to the fact that many people with HCV may 
actually be asymptomatic, and may not seek medical care because they do not know they 
are infected (CDC, 2008). Also, HCV infected individuals may be more likely to be a 
member of marginalized groups that may not have access to basic medical care.  
Standard public health efforts seek to identify host, agent and environmental 
factors and manipulate them in order to control exposure and transmission of the disease 
(Heymann, 2004). Unfortunately for the IDU population, multiple factors enable 
infection and reduce the opportunity for identification (Hagan et al., 2007). In countries 
where at least some effort to combat HCV exists, those efforts largely focus on harm 
reduction (Madden & Cavalieri, 2007). The fact that no country has been successful in 
preventing large numbers of new cases has led many researchers to question the 
effectiveness of the harm reduction approach to HCV infection (Hagan, 2007; Mateu-
Gelabert, et al. 2007; Madden & Cavalieri, 2007). 
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Human Immunodeficiency Virus (HIV)/HCV co-infection 
HIV and HCV share many risk factors (e.g., injection and sexual behaviors). 
Alberti and colleagues (2005) found 30-50% of HIV-infected patients are co-infected 
with HCV. There are approximately 300,000 co-infected individuals in the U.S., which 
represents 15-30% of HIV infected individuals and 5-10% of HCV infected individuals 
(Andersson & Chung, 2006; Mayor et al., 2008, Strader, 2005). Gonzalez & Talal (2003) 
found HIV/HCV co-infected individuals are likely to not have access to treatment for 
their HCV because of medical contraindications, such as active alcohol or substance use, 
past or current history of psychiatric disorders, advanced progression of AIDS, HCV 
genotype, HCV viral load or other comorbidities. In addition, HIV/HCV co-infected 
individuals are generally older, male, and are IDUs (Backus, Boothroyd, & Deyton, 
2005). There are considerable data indicating that HIV/HCV co-infection has a negative 
effect on the natural course and response to antiviral therapy for both types of infections 
(Alberti, 2009). One of the most significant problems with HCV however, is that HCV is 
estimated to be at least 10 times more infectious per unit of blood than HIV, hence 
requiring less exposure to reach the current high prevalence (Paintsil et al. 2010). There is 
no available published research study or information about the impact of HIV/HCV 
comorbidity in a U.S. urban population (Alberti, 2009). 
Given these rates and the evidence at hand, there is a need to deliver HIV/HCV 
prevention programs in conjunction, with the important caveat that existing HIV 
programs must be revamped as well. This point is discussed further in the discussion 
section of this dissertation. 
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Risk factors for individuals of Hispanic/Latino origin  
According to the U.S. Census Bureau, Hispanics/Latinos are the fastest growing 
and the largest minority group in the U.S. (Cheung, 2005). Approximately 40 million 
people of Hispanic/Latino descent reside in the continental U.S. (Cheung, 2005). Little is 
known about HCV prevalence and transmission rates in non-Caucasian populations 
(Azócar, 2003). A study conducted by Azócar (2003) on 235 participants of Puerto Rican 
ancestry found that within the inner-city Latino population, the HCV seroprevalance rate 
of 8% was strikingly higher than that previously found among the general population. 
According to Azócar, this difference most likely reflects different behavioral patterns. 
The participants of this study resided in a densely populated area with a high 
unemployment rate, unstable marital status and high rates of incarceration (Azócar, 
2003). Azócar’s study found the following significant associations with an increased risk 
of HCV infection: (1) using intravenous drugs, (odds ratio [OR]=30.4), (2) using inhaled 
drugs (OR=26.44), (3) using drugs (injected, inhaled, or smoked) during sex (OR=18.67), 
(4) sharing objects (in this case, sharing of cutting edge objects such as nail clippers, 
scissors and razors, etc.; OR=13.75) and (5) having a history of STDs (OR=4.59).  
In another study looking at a sample of HCV-positive Hispanic/Latino patients in 
the Texas/Mexico border region, researchers discovered that tattooing was the single 
most important independent risk factor for 84% of the sample (Hand & Vasquez, 2005). 
The authors concluded that the higher prevalence of HCV infection in Hispanics/Latinos 
might be due to unique risk factors such as tattooing and other high-risk behaviors among 
Hispanic/Latino IDUs (Hand & Vasquez, 2005). 
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A study conducted by Cheung (2005) found that Mexican-Americans had a higher 
anti-HCV antibody positivity rate than Caucasians (2.1%; 95% CI=1.7, 2.6), and were 
more likely to be viremic (73.6%; 95% CI=66.8, 81.2). However, this study found that 
after adjusting for other risk factors, ethnicity and race were not independently associated 
with HCV infection. It also found that Hispanics/Latinos, when compared to Caucasians, 
were more likely to be co-infected with HIV (20.4 % vs. 3.9%; Cheung, 2005).  
Since Hispanics/Latinos are the most rapidly increasing minority group in the 
U.S,. more research is needed in order to determine barriers to initiating antiviral therapy 
as well as reasons for early treatment and to investigate any potential differences between 
various Hispanic/Latino populations (Cheung, 2005). Being of Hispanic/Latino ethnicity 
alone does not automatically double or triple chances of HCV infection, but being a 
Hispanic/Latino IDU does seem to carry a disproportionately increased risk for HCV 
infection compared to White, non-Hispanic/Latino IDUs (Estrada, 2005). In addition, 
several other risk factors converge on Hispanic IDUs, essentially increasing the infection 
risk considerably. 
Demographics 
It is theorized that several socio-demographic and lifestyle factors such as race 
and ethnicity, income, educational status and marital status may be strongly associated 
with HCV infection; some of these factors have been associated with more serious 
hepatitis C outcomes (Dev et al., 2006; Fujita et al., 2006; Hezode et al., 2003; NIH, 
2002, Scognamiglio et al., 2007). Current theories do not address race and ethnicity 
differences between Hispanics/Latinos of different countries of origin. Research question 
#1 seeks to expand the current research in this area by examining whether individuals of 
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different Hispanic/Latino ethnic backgrounds follow the same pattern of associations as 
other, broader studies (such as studies looking at HCV infection in the overall IDU 
population, not just among Hispanics/Latinos).  
To date, there are few studies that look exclusively at demographic factors and 
their association with HCV infection (Lopez et al., 2007). Trooskin (2010) utilized a 
cross sectional design to study 503 Hispanics/Latinos in the Philadelphia area and 
assessed their risks for HCV. Trooskin found that individuals who made more than 
$15,000 per year were more likely to have an HCV risk factor (not HCV infection) than 
people making less than $15,000 (OR=2.3; 95% CI=1.2, 4.5). Country of birth was also 
identified as being strongly associated with having an HCV risk factor, with U.S.-born 
Hispanics/Latinos being more likely than non U.S.-born Hispanic Latinos to have an 
HCV risk factor (OR=3.4; 95% CI=1.9, 6.0; Trooskin et al, 2010). Finally, being age 41 
or older was significantly negatively associated with having an HCV risk factor 
compared to those aged 18-24 (OR=0.5; 95% CI=0.25, 0.99). It is important to 
understand that Trooskin examined whether these demographic factors were associated 
with having an HCV risk factor, not being HCV infected.  
 Being male as well as younger may also be associated with an increased risk of 
being HCV infected. Siddiqui et al. (2008) examined very limited demographic factors in 
a large cohort of urban HCV patients in Detroit. Of the 2,739 HCV positive patients in 
the study, most (65%) were males (Siddiqui et al., 2008). In addition, most risk factors 
were reported by patients in their 20s (Siddiqui et al., 2008). It is important to know that 
this study only included 2.1% “Hispanics and Asians” (Siddiqui et al., 2008). Despite this 
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however, this study offers some evidence that males of younger age are more likely to be 
at risk for HCV infection. 
Personal networks 
 The IDU personal network is an important factor that requires attention. An IDU 
personal network includes people an IDU may have a social relationship with: an 
injecting partner, a sex partner, a family member, etc. Changes in the personal network of 
an IDU have been shown to cause changes in the individual’s risk taking behavior 
(Costenbader, Astone, & Latkin, 2006). To date, there are no studies that examine the 
risk factors associated with IDU networks and HCV infection, but there are many studies 
that study HCV infection and personal networks. These studies shall serve as a proxy for 
the contribution of personal networks on HCV infection. 
 Wylie, Shah, and Jolly (2006) found that the likelihood of exposure to blood 
borne pathogens is a multifactorial process, primarily dependent on the risk behaviors an 
individual practices and the likelihood that a susceptible individual will come into contact 
with an infected individual, essentially increasing or decreasing the risks associated with 
a risk behavior. Infected individuals are brought into contact with one another in the 
context of personal networks (Wylie et al., 2006). The rate of pathogen spread through 
these networks may be affected by the overall structure and size of the network (Treolar 
et al., 2011). 
 Research among IDUs and their networks have identified many variables that 
may be associated with transmission risk (Wylie et al., 2006). Variables identified 
include the number of network members, the presence of family members or spouses 
within the network, higher network density, the setting where injection takes place, 
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turnover of network members, and the pooling of financial resources within networks for 
the purpose of obtaining drugs (Treolar et al., 2011). Racial/ethnic differences in HIV 
prevalence have also been at least partially explained by taking into account the differing 
network characteristics of different ethnic groups (Mayor et al. 2008). 
 An individual may have a set of risk factors that contribute to HCV infection. 
Within the context of a personal network, there is a different set of risk factors that 
emerge. Studying this hierarchy of risk factors is an important step that must not be 
ignored (Wylie et al., 2006). Both individual and network level concepts assist in 
characterizing and comparing the transmission of HCV, and determining the underlying 
patterns that drive the social connections between individuals that may favor or hinder 
transmission of HCV infection (Wylie et al., 2006).  
Several studies have examined IDU personal network relationships on sexually 
transmitted infections, risky sexual behaviors and injection drug use behaviors 
(Rothenberg et al., 1998; Latkin, Forman, Knowlton, & Sherman, 2003; Latkin, Hua, & 
Forman, 2003; Latkin et al., 1994; Latkin et al., 1995; Latkin et al., 1996; Suh et al., 
1997). For example, in a study examining the relationship between network 
characteristics and sexual risk behaviors, Latkin and colleagues found that increased 
network size increased the odds of exchanging money or drugs for sex and having 
multiple male partners (Latkin et al., 1994). Network density defined as networks with 
more connected relationships, was inversely associated with exchanging money or drugs 
for sex (Latkin, Hua, & Forman, 2003). In another study assessing the association 
between network characteristics and frequency of injection drug use, absence of a 
partner, size of drug network and network density were significantly associated with 
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injecting at least once a day in the adjusted analysis (Latkin et al. 1995). Larger drug 
networks were also shown to influence the likelihood of injecting in shooting galleries as 
well as a higher likelihood of sharing needles (Suh et al., 1997). This has also been 
shown in other studies where large networks were associated with frequent needle 
sharing, and being more central (or linked with more people) in a network is associated 
with needle sharing (Latkin, Hua & Forman, 2003; Mandell et al., 1999; Friedman & 
Aral, 2001). 
Sexual risk factors 
Sexual behavior has been theorized to be associated with HCV infection as well 
(Solomon et al., 2011). There are several cases on record where HCV infection could 
only be attributed to an HCV-infected sexual partner, as no other risk factor existed 
(Matthews et al., 2007). Most of this research was conducted in Europe, and to date there 
is no research that study Hispanic/Latino sexual risk factors for HCV infection 
exclusively, let alone study Hispanics/Latinos of different ethnic backgrounds. Research 
question # 2 would be the first attempt to examine sexual risk factors in Hispanic/Latino 
populations by different ethnic backgrounds in the U.S. This study would also be the first 
to investigate the strength of association of sexual risk factors within different 
Hispanics/Latinos as it pertains to their ethnic background. 
Evidence continues to accumulate in support of the sexual transmission of HCV 
(Solomon et al., 2011). There are several cases on record where HCV infection could 
only be attributed to an HCV-infected sexual partner (Matthews et al., 2007).  HCV RNA 
has been detected in bodily fluid samples (saliva and semen) of individuals who have are 
HCV positive, suggesting a potential sexual route of HCV exposure (Briat, Dulioust, 
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Galimand, et al., 2005; Liou et al., 1992). The infectivity of these fluids is unknown and 
studies have not been able to conclusively isolate exposure to saliva or semen as the 
cause of transmission of the HCV virus (Briat et al., 2005; Alary et al., 2005). 
Epidemiological studies examining an association between sexual contact and HCV 
transmission, conducted among various populations, including monogamous couples, 
where one partner is HCV positive and the other is HCV negative, HIV serodiscordant 
couples, heterosexuals, and men who have sex with men have been inconclusive but 
suggest risk may be positively correlated with the number of sexual partners and when 
the sexual partner was HIV/HCV co-infected (CDC, 2010; Leurez-Ville 2000; Nyamathi 
et al., 2002). Research with serodiscordant monogamous couples reveal that the rate of 
HCV transmission is low, ranging from 0.0-0.6% per year (Ghosn, Leurez-Ville, & 
Chaix, 2005; van de Laar et al., 2010). Infection risk is however slightly higher among 
heterosexuals who have multiple sex partners or are exposed to STDs, with rates ranging 
from 0.4-1.8% per year (Terrault, 2002; van de Laar et al., 2010). 
 MSMs are an example of a group where HCV incidence and prevalence is 
increasing, especially among HIV positive MSM (van de Laar et al., 2010; van de Laar et 
al., 2007; Danta et al., 2007; Gambotti et al., 2005; Fierer, 2010). For example, a study by 
van de Laar and colleagues (2007) documented HCV incidence among HIV-positive 
MSM to be 0.87 per 100 person-years (95% CI=0.28, 2.03), while the incidence among 
HIV-negative MSM was much lower (0.00 per 100 person-years [95 % CI=0.00, 0.05]). 
Another study looking at the sexual risk factors for HCV in MSM found that newly HCV 
infected HIV-positive MSM were significantly more likely to report unprotected 
receptive anal sex with ejaculation from their partner (Fierer, 2010). 
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 It has been theorized that HCV sexual transmission may result from mucosal 
disruption during sexual contact (Danta et al., 2007; Filippini et al., 2001). MSM are 
much more likely to engage in these mucosally traumatic sexual practices (“rough” 
sexual techniques such as anal fisting, use of anal sexual devices and frequent group sex, 
all of which may cause lesions in the rectal tissues and possibly lead to blood contact), 
and could serve as a means for permucosal HCV transmission (Danta, et al., 2007; 
Gambotti et al., 2005). 
Another dimension of sexual risk of HCV involves the combination of sex and 
drug use. People who engage in sexual activity under the influence of drugs (either 
injected or not injected) are more likely to engage in “risky sexual practices,” such as 
lack of protection and “sexual transactions” (Floyd et al., 2010; Dunkle, Wingood, Camp 
& DiClemente, 2010). Sexual transactions occur as a means to procure drugs in the 
absence of money and are much more likely to result in lack of protection (Dunkle, 
Wingood, Camp & DiClemente, 2010). 
As of today however, the evidence for the sexual transmission of HCV is still 
deemed “unclear” (CDC, 2010). New techniques, such as second and third generation 
anti-HCV assays that produce lower false positives, as well as more rigorous study 
methodology aimed at assessing the independent contribution of sexual activity in HCV 
infection will greatly enhance the ability to quantify sexual contact as a risk factor 
(Matthews et al., 2007). 
The CDC collects detailed risk factor data for acute HCV infection through the 
Acute Hepatitis Sentinel County Surveillance System. Between 1995 and 2000, up to 
18% of individuals with acute HCV infection reported sexual contact as their only risk 
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factor for infection (CDC, 2008). This statistic suggests that sexual transmission does 
contribute significantly to the total burden of HCV infection in the U.S. 
Intravenous drug use (IDU)/Drug paraphernalia 
IDU is the leading risk factor for HCV infection (Armstrong et al., 2006; 
Birkhead et al., 2007; Zule & Bobashev, 2008). Currently, IDU accounts for 
approximately 10-35% of the annual incidence of HCV cases in the U.S. through 
exposure to blood-contaminated drug injection equipment (Amon et al., 2008). 
Prevalence rates of 60% to 80% have been observed in the IDU population (Ministerial 
Advisory Committee on AIDS, Sexual Health and Hepatitis C Subcommittee, 2006; 
National Institutes of Health, 2002; Roy et al., 2002; Roy, Nonn, Haley & Cox, 2007). A 
substantial percentage of HCV infections, estimated at 60%, can be traced back to 
intravenous injection (Hellard, Sacks-Davis, & Gold, 2009; Grebely & Dore, 2011). 
In 2006, injection drug use was responsible for up to 16% of new HIV cases in 
the U.S. (SAMHSA, 2009). This statistic however, pales in comparison with the 
percentage of HCV cases that may be attributed to injection drug use. Injection drug use 
is responsible for an inordinate number of HCV infections in the U.S. and abroad, 
approximating 90% worldwide and up to 60% in the U.S. (Hellard, Sacks-Davis, & Gold, 
2009). Needless to say, IDU is an established, consistent and reliable predictor of HCV in 
all populations studied to date (Hagan, Pouget & Des Jarlais, 2011). Given the fact that 
Hispanics/Latinos from South America and the Caribbean are grossly underrepresented in 
the scientific literature, research question #3 seeks to answer whether different 
Hispanic/Latino ethnic backgrounds follow the same trends as reported in national 
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studies/surveys, and if differences are discovered, are those differences statistically 
significant. 
Injection drug use puts the user at a very high risk for exposure to blood-borne 
pathogens such as HIV and hepatitis viruses (Substance Abuse and Mental Health 
Services Administration [SAMHSA], 2009). HCV can survive in a syringe for up to 63 
days, demonstrating the viability of HCV and the prolonged duration of potential 
transmission through needle sharing (Paintsil et al., 2010). There is a broad base of 
literature that demonstrates elevated HCV risk in association with injection drug use, 
particularly among injectors who share injection equipment and have injected for long 
periods of time (Brewer et al., 2006; Hagan et al., 2006; Lert, 2006; De et al., 2007; 
Firestone Cruz et al, 2007; Morissette et al., 2007; Vickerman et al., 2007; Lee et al., 
2008; Shannon et al., 2008; Oliveira et al., 2009). The risk for infection is further 
exacerbated by behaviors such as needle sharing, reusing unclean drug paraphernalia, 
sharing dirty water, backloading (sharing prepared drug by pulling the plunger from the 
back of the syringe), frontloading (sharing prepared drug by removing the needle from 
the syringe), jacking (drawing blood into the syringe then injecting a portion of the 
blood/drug mix and repeating), etc. (SAMHSA, 2009). 
Drug paraphernalia have been proposed as a potential route of HCV infection (De 
et al., 2009; Hagan et al., 2001). Research into the links between shared drug use 
paraphernalia and HCV infection, particularly in the absence of injection with a 
contaminated syringe is a largely unexplored area of study (Hagan et al., 2001). Items 
such as cookers, cottons, and rinse water are commonly used by IDUs and sharing of this 
ancillary equipment has been shown to be a very common practice in the U.S. (Koester et 
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al., 1996, Gillies et al., 2010). In addition, studies have found viable HCV viruses on 
cookers, cottons, and in water (Crofts et al., 2000). It is theorized that due to the HCV 
virus’ “hardiness,” it can be deposited in these cookers via a contaminated syringe of one 
user, and be drawn up the syringe of another person who uses the same cooker, even if it 
is days later (Koester et al., 1996). The same can hold true for cottons, as they are used to 
wipe the injection site clean, as well as the syringe. If a dirty syringe is wiped with a 
piece of cotton and then that same cotton is reused by a separate person on a different 
needle, a pathway for infection has been created. Rinse water is also another potential 
vector for HCV infection, as a person can clean their syringe (potentially depositing the 
HCV virus) and then a second person may infect their needle due to the reusing of the 
rinse water either to rinse their syringe or to prepare the drug solution. With these three 
items, an HCV-infected IDU can still infect other individuals without a needle being 
shared between them.  
In the late 1980s and early 1990s, needle exchange programs (NEPs) surfaced as a 
possible effective way to reduce infections (at the time, mainly HIV, but HCV soon 
thereafter) in the IDU population (Hagan et al., 1995; Hagan et al., 1999). Initial studies 
have shown that NEPs do not have any significant effect on the risk of HCV infection, 
even though the programs have had a significant positive effect in the reduction of HIV 
infections in IDU’s (Hagan et al., 1999; Moss & Hahn, 1999; Heimer, 1998). Further 
studies have determined that the benefits of NEPs on HCV transmission are unclear 
(Mansson et al., 2000; Wright & Tompkins, 2006). It has been theorized that the 
difference in prevalence correlating with such prevention efforts may be due to 
discriminatory sharing of equipment and needles in which individuals choose with whom 
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they will share their instruments (Burt et al., 2007). Others propose that duration of IDU 
is a stronger risk factor for HCV infection and suggest the difference in prevalence rates 
may be associated with duration of usage rather than needle sharing behaviors (Diaz, et 
al., 2001). 
HCV Prevention Studies  
HCV prevention is still in its infancy. Although there is much work that has been 
done with regard to HIV prevention among IDUs, we still do not know how to 
successfully prevent HCV infection in this group (Mateu-Gelabert et al., 2007). HCV 
treatment programs for intravenous drug users have not been included as part of the 
efforts to reduce the impact of the HIV epidemic (Grebely et al., 2007). Whether as part 
of a combined HIV/HCV prevention program or a program specifically tailored to HCV 
alone, much work remains to be done, particularly in the Hispanic/Latino population. The 
high incidence and prevalence of HCV in IDUs makes prevention efforts a very difficult 
task (Shepard, Finelli & Alter, 2005). There are however, a few studies that attempted to 
study transmission of HCV in this population, none of them focusing specifically on 
Hispanic IDUs.  
There have been only two studies in the past 10 years that examined the effect of 
behavioral interventions on HCV seroconversion among IDUs (Hagan, Puget, & Des 
Jarlais, 2011). Garfein and colleagues (2007) and Stein (2009) assessed the effects of 
peer education interventions (PEI) and motivational interviewing (MI) in cohorts of IDUs 
in multiple sites in the U.S. The Garfein study was a multi-site randomized controlled 
trial looking at PEI versus equal-attention controls over a period of six sessions in a 
cohort of IDUs (Garfein et al., 2007). The reported odds ratios for the peer education 
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interventions was 1.15 (95% CI=0.72, 1.82), indicating that there was no difference 
between the treatment group and the control group (Garfein, 2007). Stein (2009) also 
utilized a randomized controlled clinical trial utilizing MI in a cohort of IDUs in 
Providence, RI. The reported relative risk was 1.28 (95% CI=0.49, 3.35), also indicating 
that there was no significant difference between the groups (Stein, Herman & Anderson, 
2009). 
NEPs have also been studied as a potential intervention to reduce HCV 
transmission. Hagan and colleagues studied groups of IDUs in Tacoma (1995) and 
Seattle (2004). Utilizing an observational case-control study, Hagan compared 
participants that either ever participated in a NEP or never participated in a NEP. The 
reported OR was 0.14 (95% CI=0.03, 0.62), indicating that participating in an NEP had a 
significant, although small effect on HCV transmission (Hagan et al., 1995). Hagan and 
colleagues also looked at a cohort of IDUs in order to determine if using an NEP had any 
effect on HCV transmission. The reported hazard ratio (HR) was 1.4 (95% CI=0. 9, 1.9), 
suggesting that the results were not significant. Holtzman and colleagues (2009) obtained 
similar results when they studied a cohort of IDUs in a multisite study. The reported OR 
was 1.41 (95% CI=0.96, 2.01). NEPs may have some effect of the transmission of HCV 
in the IDU population, however NEPs are not legal in Florida, therefore this option would 
not be accessible to participants living in Miami-Dade County. 
Summary 
 HCV has been identified as the most common blood infection in IDUs. 
Prevalence of HCV infection in this group is estimated to be as high as 75%. The main 
mode of HCV transmission is through percutaneous exposure to HCV infected blood or 
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blood products. As of today, the most common means of exposure to HCV infected 
blood/blood products is through IDU and the use of shared IDU equipment (needles, 
cookers, cottons, water). Although there is no concrete evidence for other infection 
pathways, unprotected sexual activity is quickly gaining attention as a potential alternate 
infection route, particularly among MSM who do not inject. Other risk factors for HCV 
infection include demographics and personal injection networks.  
 Given the fact that HCV seems to follow the same pattern of infection as HIV, 
and that between 30-50% of HIV-infected patients are also co-infected with HCV, it may 
be effective to deliver an HCV prevention program in conjunction with an HIV-
prevention program. Unfortunately, there are certain physiological characteristics of the 
HCV virus (higher infectivity rate and “hardiness” of virus outside the human body) that 
may hinder these efforts and warrant a separate and focused intervention solely for HCV. 
Current interventions are in an infancy state and there has not been one intervention that 
has proven effective against HCV infection. 
 Hispanics/Latinos currently comprise the fastest growing and largest minority 
group in the U.S. In addition, several studies have found that Hispanics/Latinos have a 
much higher prevalence rate of HCV than Caucasians. Finally, Hispanics/Latinos are not 
well represented in the literature. Most studies group people of Hispanic/Latino 
background into large aggregate groups without considering different cultural aspects of 
their different nationalities (e.g., Cubans, Puerto Ricans, Dominicans, Mexicans), which 
could affect the reported HCV infection rates among Hispanics/Latinos and may differ 
among the groups.  
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CHAPTER III 
METHODOLOGY 
 The main purpose of this study is to attempt to assess the association between 
identified risk factors for HCV infection in the Hispanic/Latino intravenous drug using 
(IDU) population and HCV infection. The sample selected for the proposed study was 
from Miami-Dade County, Florida. This study is based on an original CDC-funded study 
that primarily examined the HCV prevalence among Hispanic/Latino IDUs in South 
Florida (parent study). The current study is a secondary research analysis of data obtained 
from the parent study. 
Description of parent study 
This study utilizes data taken from an original CDC-funded study entitled 
“Prevalence of HIV, Hepatitis B & C Virus Infections, and Associated Risk Factors 
among Hispanic IDUs,” CDC grant # U65/CCU423371. The main differences between 
the parent study and this supplemental study are, 1) the parent study did not calculate the 
strength of associations between risk factors and HCV infection alone, focusing primarily 
on comorbid individuals, and 2) the unit of analysis in the parent study was “Hispanic 
IDUs,” whereas the unit of analysis in this study will be specific Hispanic/Latino 
ethnicities, specifically: Mexican, Central American (Belize, Costa Rica, El Salvador, 
Guatemala, Honduras, Nicaragua, and Panama), South American (Argentina, Bolivia, 
Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and 
Venezuela), Puerto Rican, Cuban, and Dominican individuals.  Finally, the parent study 
did not develop the framework for a theoretically based, comprehensive HCV prevention 
intervention for Hispanic/Latino IDUs. 
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The parent study used a cross-sectional study design and collected information on 
the prevalence of selected diseases. There was no intent to educate the participants 
beyond providing them with standard information after the completion of the 
questionnaire. A total of 240 Hispanic/Latino drug injectors (both men and women, and 
both HCV positive and negative) across Miami-Dade County, FL were enrolled into the 
study and were surveyed. They were told that the study was investigating rates of HIV 
and hepatitis, as well as other issues such as alcohol abuse, sexual behavior, depression, 
and acculturation. The participants were selected utilizing a snowball sampling technique, 
utilizing participants as informants in order to gain access to other participants. This 
technique, while not providing a representative sample, proved to be the most productive 
given the study population. Given the high prevalence of IDUs in certain areas of Miami-
Dade County, the targeted recruitment areas included: downtown Miami, North Miami, 
and Homestead. 
Inclusion criteria for the main study included: injecting opiates and/or cocaine 
and/or amphetamines for at least three months, using substances at least weekly for the 
past 30 days, and being 18 years of age or older. After the participants were properly 
consented by study personnel pursuant to University of Miami IRB, they completed a 
computer assisted, self administered, in-depth survey (The Modified AIDS Risk Behavior 
Questionnaire) with 248 items that measured injection and non-injection drug use, 
alcohol use, sexual history, drug user networks, acculturation, information on HIV, HCV 
and other STIs, and demographic data (Chitwood, Comerford, Kitner, Palacios, & 
Sanchez, 2001; Weiss, Chitwood & Sanchez, 2008). This instrument required 
approximately one and a half hours to complete. This instrument been shown to be valid 
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and reliable in other drug using populations, with kappa coefficients ranging from 0.44 
for nondichotomous variables to 0.72 for dichotomous variables (Ball, 1967; McElrath, 
Chitwood, Griffin, & Comerford, 1994; Stephens, 1972). 
Sample size calculation and power analysis 
Given that IDU was an original inclusion criterion, all original participants were 
eligible for this study. In order to ensure that there were enough participants to perform 
analyses, power calculations were conducted. An important factor in planning a scientific 
study is to identify as appropriate sample size to achieve sufficient power to detect the 
hypothesized effect. 
 The power of a study is defined as the probability of detecting a statistically 
significant effect (Purcell, Cherny, & Cham, 2003). Furthermore power calculations are 
useful to help determine if a study is underpowered, or if it is possible to find the smallest 
detectable effect size given the actual sample size. A requirement for computing power 
calculations is to make assumptions regarding differences about study effects. Several 
software tools are available to make power calculations practical, one of which is a 
Generic Power Calculator (Purcell, 2003). The Generic Power Calculator, which is a 
computational tool, was utilized to implement power calculations using quantitative traits 
on both HCV+ and HCV- subjects to determine if the study had enough subjects 
available to show statistically significant result. The result of the power analyses 
indicated that with a given N of 240, and a HCV prevalence of 75.8% in the sample, this 
study would have 80% power (α=0.050, two-tailed) to reject the null hypothesis of zero 
correlation between the variables. 
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A minimum sample was calculated and considerations ensuring that multivariate 
models had sufficient ability to detect differences were made. Peduzzi et al. (1996) 
provides the following equation that provides guidance for a minimum number of cases 
and the  maximum allowable number of independent variables that should  be included in 
analyses, in this case, beginning with the univariate analyses: 
N = 10 k / p 
In the above equation, N is the estimated sample size, k is the number of covariates 
(independent variables) and p is the proportion of positive cases in the population. The 
data reveal that the proportion of positive HCV cases (p) in the selected population is 
0.758. There were 240 participants in the study (N), so in order for that number to be an 
adequate sample for this study, a maximum of 18 covariates (k) could be included in the 
model. 
Dependent variable 
 HCV serostatus was the dependent variable in this study. The original study 
included serologic studies of all participants. HCV testing was performed at the University 
of Miami Hepatology Laboratory.  HCV antibodies were detected by EIA (Anti-HCV 3.0 
ELISA Test Kit Ortho Diagnostic Systems Inc., Raritan, NJ). HCV serostatus was 
operationalized as a dichotomous variable, which was coded: 0=negative, 1=positive. 
Correlations of demographic variables with HCV status are summarized in Table 1. 
Independent variables   
The independent variables used in this study are grouped in three overall risk 
factor profiles: demographic risk factors, sexual risk factors and injection risk factors. 
Demographics are always an important variable to include in this type of study, 
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particularly when very little information about the population as well as the incidence and 
prevalence rate of the selected outcome (HCV) is available. Risk may vary by location, 
age, gender, etc. The location of this study will not vary (Miami, Florida). Age and 
gender, however, have been captured as independent variables in order to study any 
fluctuation in risk given these two demographic variables. In addition, the data collected 
includes information on educational level, employment, income, marital status, and 
residency. 
Sexual risk factors have been included in this study given the emergence of 
studies indicating that HCV may be transmitted via sexual contact (Terrault, 2002; van de 
Laar et al., 2007). Sexual risk factors that were a part of the original study are included in 
this study in order to ascertain their effects on HCV infection on this population. There is 
an emerging body of literature that suggests that unprotected sex may be independently 
associated with HCV infection (Terrault, 2002). As such, it is important to understand if 
and how sexual risk factors are associated with HCV infection in the Hispanic/Latino 
IDU population. 
Injection drug use is the main mode of transmission of HCV. As such any 
variable associated with injection drug use was included in this study. Particular attention 
was paid to use of dirty needles (needle sharing), use of dirty paraphernalia, and 
frequency of injection. Personal networks are also an important risk factor for HCV 
infection and therefore information on networks were included in this study. As stated in 
the literature review, personal networks add another layer of risk and may influence the 
individual’s own risk-taking behavior (Costenbander, Astone & Latkin, 2006). In order to 
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study the possible effects of the percentage of people who inject drugs in an individual’s 
personal network, this variable has been included in the study. 
The independent variables associated with the demographic risk factor profile are: 
gender, which can be male, female or transgender; age, which refers to the current age at 
the administration of the questionnaire as was dichotomized as “young” (18-24) and 
“older” (25 and older); education level, which refers to whether the participant has 
completed high school; employment refers to whether the participant was employed 
(either full-time or part-time) at the time the questionnaire was administered; income 
refers to the annual reported gross earnings for the participant at the time of the 
questionnaire; marital status refers to the current legal status at the time of the 
administration of the questionnaire; residency reports on the current reported living 
situation at the time of the questionnaire; Hispanic/Latino ethnic background refers to the 
self-reported Hispanic/Latino ethnic background. Some ethnicities were grouped as 
regions due to the fact that there were few participants who reported being from a 
specific ethnic background (i.e., “Peruvian” or “Costa Rican”) and the group was not 
large enough to detect statistically significant results between all groups. Grouping ethnic 
backgrounds in this way produced several “small groups.” Given that one of the aims of 
this study was to see if there were different risk factors in different ethnic groups, it was 
decided to leave the smaller groups intact to determine if they would produce statistically 
significant results. Number of years in the U.S. refers to the number of years 
continuously living in the U.S. at the time of the administration of the questionnaire; born 
the U.S. refers to whether the participant was born in the United States regardless of their 
ethnic background. 
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The independent variables associated with the sexual risk factor profile were: age 
at first sexual encounter, which refers to whether the participant reported age at first 
sexual encounter of younger than 14 or 14 and older. The age of 14 was the median age 
reported by the sample as the age when they first had a sexual encounter. Dividing the 
sample further by either using age as either a continuous or categorical variable with 
several groups produced very uneven groups that did not yield statistically significant 
results. Given this, the variable “age at first sexual encounter” was dichotomized. 
Number of sex partners in the last three months refers to the number of sexual partners in 
the 3-month period prior to the administration of the questionnaire; number of sex 
partners in a lifetime refers to the self-reported total number of sexual partners in the 
individual’s lifetime. The variable “sex partners in the past 3 months” did have 66 
missing cases, and those were treated as having no sex partners. 
The independent variables associated with the injection risk factor profile were: 
use of a dirty cooker, which refers to the percentage of time the participant used a “dirty 
cooker” as defined by using it immediately after someone else had used it without it 
being cleaned/replaced with a new one; use of a dirty cotton, which refers to the 
percentage of time the participant used a “dirty cotton” as defined by using it 
immediately after someone else had used it without it being cleaned/replaced with a new 
one; use of dirty rinse water, which refers to the percentage of time the participant used a 
“dirty rinse water” as defined by using it immediately after someone else had used it 
without it being cleaned/replaced with fresh water; use of a dirty needle/syringe refers to 
the percentage of time the participant used a “dirty syringe” as defined by using it  
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immediately after someone else had used it without it being cleaned/replaced with a new 
one. 
Several of the independent variables examined injection frequency. These 
variables were: weekly injection frequency, which measured the number of days the 
participant injected in the week prior to the administration of the questionnaire; daily 
injection frequency refers to the number of times per day the participant injected (the last 
time the participant injected) prior to the administration of the questionnaire.  
Finally, there was one variable that examined the participant’s personal injection 
network. The variable, IDU’s in personal network, represented the percent of people in 
the participant’s social network who currently injected any drug. The possible answers to 
all variables are summarized in Tables 1 and 2. 
Data analysis 
The data analysis used in this study included: 1) univariate (descriptive) analyses, 
2) bivariate analyses, and 3) multivariate logistic regression analyses. Finally, in order to 
ensure that the final model included only the variables that contributed the most to the 
final model, ensuring that no further improvement is necessary, a backward logistic 
regression was performed.  All of the analyses were conducted in SPSS version 19 (IBM, 
2010). 
The descriptive statistics (univariate analyses) in this study included frequency 
distributions as well as measures of central tendency. For the frequency distributions, the 
number and percentage of each occurrence were presented for all variables in the study. 
These included the HCV serostatus of the participants, as well as the study domains 
(demographics, sexual risk factors, and injection risk factors). Examining the 
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characteristic variables helped in determining whether each group (HCV + vs. HCV -) 
was equally represented in the study. 
In the bivariate logistic regression portion of the study, HCV-positive and HCV-
negative participants were compared in terms of demographic characteristics, sexual risk 
factors, and injection risk factors. The main purpose of this comparison was to ensure that 
the selected independent variable categories formed groups that were large enough for 
analyses. If the independent variable groups were not large enough or did not represent a 
hypothetical sample then the independent variables were recoded in order to more closely 
mimic a hypothetical population.  Bivariate analyses were also performed to assess 
whether there were preliminary correlations among dependent and independent variables. 
The Pearson’s Chi square (χ2) was utilized for this particular analysis. A lower p-
value informed us that the selected groups were distributed as expected and that true 
differences may be detectable between the groups. If a higher p-value was obtained, then 
the independent variables were recoded in order to maximize the correlation between the 
existing and expected (hypothetical) population. There were however, instances where 
the independent variables were recoded to be as large as possible (dichotomized), but a 
high p-value still existed. A higher p-value for the χ2 analysis however, did not cause the 
variable to be dropped from the overall analysis. Given that the selected variables proved 
to be significant in the literature review, they were still included in the initial logistic 
regression model. 
The next step in the analysis involved determining the unadjusted odds ratios 
using logistic regression for every variable in the study. The dependent variable (HCV) 
was analyzed with each independent variable separately. The results of this analysis 
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showed the relevant odds ratios (unadjusted) and significance values for each 
independent variable with the dependent variable. This was an important step because 
this analysis assisted in further defining what independent variables were associated with 
HCV infection and essentially served to shorten the list of possible independent variables 
included in the multivariate logistic regression model. A generous p-value of p < 0.20 
was applied and all variables significant at that level were included in the final logistic 
regression. 
The independent variables included two sets that were very similar and possibly 
highly correlated. In the sexual risk factor profile, the number of sex partners in the past 
three months and number of sex partners in a lifetime could potentially inflate the odds 
ratios of other independent variables in the multivariate analyses. Similarly, in the 
injection risk factor profile, weekly injection frequency and daily injection frequency 
could influence the odds ratios as well. 
The variable number of sex partners in the past three months also had a slight 
irregularity. As collected, the data show that only 174 participants answered the question 
“how many sexual partners have you had in the past 90 days?” A total of 66 participants 
left the question blank. In order to ensure equitable groups when performing all the 
analyses, it was assumed that a blank response meant that the participant did not have a 
sexual partner in the past three months and the variable was converted so that a blank 
answer equated zero. 
This issue of multicollinearity was addressed by examining the calculated VIF 
(variance inflation factor) for these four variables. VIF is defined as an index of the 
amount that the variance of each regression coefficient is increased relative to a situation 
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in which all of the predictor variables are uncorrelated (Cohen et al., 2003). A VIF of 5 or 
less is normally deemed as an acceptable VIF before multicollinearity becomes a 
problem. In order to ensure that the interaction between these variables did not affect the 
odds of other variables in the multivariate analysis, the “collinearity” test (in SPSS) was 
performed on these variables prior to beginning the analyses. The calculated VIFs on 
these four variables were: number of sex partners in the past 3 months (VIF = 1.185); 
number of sex partners in a lifetime (VIF = 1.185); weekly injection frequency (VIF = 
1.159); and daily injection frequency (VIF = 1.157). Given that all calculated VIFs were 
well below the suggested VIF of five, all four variables remained in the bivariate analyses 
and were included in the multivariate model. 
In the multivariate analysis portion of the study, all significant variables (at p < 
0.20) were included in a single logistic regression model. Final odds ratios and p-values 
were obtained and this analysis determined which of the original 20 variables, controlling 
for each other, had the most effect in predicting the HCV serostatus of the study 
population. At this point, the final model was produced and variables were categorized as 
either significant at the p < 0.05 level, or approached significance at the p < 0.10 level. 
Any variables in the multivariate model which were not significant at the p < 0.05 level 
were categorized as “not statistically significant.” 
 Finally, a backward selection logistic regression analysis was conducted on the 
variables that were initially found to be significant in the preliminary bivariate analyses. 
With the backward selection method, only those independent variables that remained 
significant at the p < 0.05 were included in the backward regression model. For the 
backward selection method, a removal criterion of p < 0.20 was selected. This high level 
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was selected because the removal criteria should be more lenient, such that not every 
independent variable is removed from the model (Hosmer & Lemeshow, 2000). The 
backward selection method is utilized in order to ensure that the final multiple regression 
model is stable and does not have too many variables. 
Summary 
The current study is a secondary research analysis of data gathered under the 
parent study. The original study was entitled “Prevalence of HIV, Hepatitis B & C Virus 
Infections, and Associated Risk Factors among Hispanic IDUs,” CDC grant # 
U65/CCU423371. The study was a quantitative cross-sectional survey. A total of 240 
Hispanic/Latino drug injectors across Miami-Dade County, FL were recruited into the 
study. All 240 of the original participants were included in this current study, since the 
only exclusion criteria would have been no intravenous drug use. 
For this study, HCV-positive and HCV-negative participants were compared in 
terms of demographic characteristics, sexual risk factors, injection risk factors, and their 
personal networks. Initially, all independent variables were analyzed using the χ2 
(Pearson’s Chi square) statistic. This allowed for the creation of statistically significant 
independent variable categories whenever possible. In addition, multicollinearity analyses 
were performed on variables suspected of measuring the same factor. 
A univariate logistic regression was then conducted in order to determine the 
unadjusted odds for HCV infection for each independent variable. Independent variables 
significant at the p < 0.20 were included in a multivariate logistic regression and adjusted 
odds were obtained. All variables significant at the p < 0.05 level at this stage were then 
subjected to a backward logistic regression in order to ensure that the selected model was 
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stable. A removal criterion of p < 0.20 at this level was established, and any variables 
above this level would be removed from the final model. Utilization of the backward 
selection method ensures the most parsimonious model, where the fewest number of 
significant variables are included in the final model.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 43
CHAPTER IV 
RESULTS 
Table 1 presents the frequency, percentages and χ2 values of the demographic risk 
factor profile. Most of the sample (75.8%) tested positive for HCV infection; the sample 
was majority male (87.5%) and most were unemployed (83.3%). In addition, the majority 
of the sample reported being unmarried (85%) and more than half of the sample 
identified themselves as Puerto Rican (66.7%). Finally, most of the participants surveyed 
stated that they were born in the U.S. (83.3%). The χ2 analyses on the demographic 
profile reveal that “Age”, “Hispanic/Latino ethnicity” and “Born in the U.S.” variables 
yielded significant findings (p < .05) when HCV+ and HCV- populations were compared. 
The variable “number of years in the U.S.” approached significance at the p = 0.10 level. 
Table 1 
Frequency, Percentages and χ2 Analyses of Demographic Variables 
 Total HCV (+) HCV (-) p- 
 N (%) N (%)  N(%)  value 
    
 Age     
  18 - 24                    16(6.7) 7(3.8) 9(15.5) 0.002 
  25 - older                   224(93.3) 175(96.2) 49(84.5)  
   
Gender     
  Male                                    210(87.5) 157(86.3) 53(91.4) 0.305 
  Female                    30(12.5) 25(13.7) 5(8.6)  
   
Employment      
  Employed 40(16.7) 33(18.1) 7(12.1) 0.281 
  Unemployed 200(83.3) 149(81.9) 51(87.9)  
 
Income     
  None 95(39.6) 74(40.7) 21(36.2) 0.753 
  < $5,000 46(19.2) 32(17.6) 14(24.1)  
  $5,000 - $9,999 33(13.7) 26(14.3) 7(12.1)  
  $10,000 - $14,999 19(7.9) 16(8.8) 3(5.2)  
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 Total HCV (+) HCV (-) p- 
 N (%) N (%)  N(%)  value 
  $15,000 - $19,999 17(7.1) 13(7.1) 4(6.9)  
  $20,000 or more 30(12.5) 21(11.5) 9(15.5)  
 
Marital status     
  Married 36(15.0) 29(15.9) 7(12.1) 0.473 
  Unmarried 204(85.0) 153(84.1) 51(87.9)  
   
Residency     
  Own home/live with  relatives 114(47.5) 83(45.6) 31(53.4) 0.298 
  Hotel/motel/boarding house 126(52.5) 99(54.4) 27(46.6)  
   
Education level     
  No high school 96(40.0) 70(38.5) 26(44.8) 0.389 
  High school or GED 144(60.0) 112(61.5) 32(55.2)  
   
Hispanic/Latino ethnicity     
  Mexican 8(3.3) 7(3.8) 1(7.7) 0.000 
  South American 8(3.3) 8(4.4) 0(0.0)  
  Puerto Rican 160(66.7) 135(74.2) 25(43.1)  
  Cuban 33(13.8) 18(9.9) 15(25.9)  
  Dominican 8(3.3) 1(0.5) 7(12.1)  
  Central American 4(1.7) 1(0.5) 3(5.2)  
  Mixed 19(7.9) 12(6.6) 7(12.1)  
  
Number of years in the U.S.       
  Less than 5 109(45.4) 90(49.5) 19(32.8) 0.100 
  5-10 years 52(21.7) 39(21.4) 13(22.4)  
  11-15 years 27(11.3) 16(8.8) 11(19.0)  
  16-20 years 21(8.8) 14(7.7) 7(12.1)  
  21+ years 31(12.9) 23(12.6) 8(13.8)  
   
Born in the U.S.     
  Yes/Born in U.S. 200(83.3) 159(87.4) 41(70.7) 0.003 
  No/Not born in U.S. 40(16.7) 23(12.6) 17(29.3)  
 
Hypothesis 1a proposed that in comparison with HCV negative individuals, HCV 
positive individuals will be less likely to be employed (employment, income) as well as 
less likely to be educated (education level) and have poorer familial stability (marital 
status, residency). Table 1 indicates that of the 182 HCV positive participants, most were 
 45
unemployed (81.9%). Of the 58 HCV negative participants, most were unemployed 
(87.9%) as well. In addition, none of the income categories showed a statistically 
significant relationship with HCV infection. These data suggest that in this sample HCV-
positive individuals do not differ statistically from HCV-negative individuals in terms of 
employment, income and education level. 
Furthermore, Table 1 indicates that 84.1% of the HCV positive participants and 
87.9% of the HCV negative participants were unmarried. Of the HCV positive 
participants, 54.4% reported living in a hotel/motel/boarding house/homeless versus 
46.6% of the HCV negative persons. The differences were not significant. Given these 
results, it is concluded that HCV positive participants in this sample do not differ from 
HCV negative participants in terms of marital status and residency status.  
Hypothesis 1b proposed that in comparison with HCV negative individuals, 
HCV positive individuals will be older (age), will be more likely to be of the male gender 
(gender). The analyses did not reveal significant differences by HCV status with regards 
to gender. Age however, showed a statistically significant relationship in all analyses. 
Table 2 
Frequency, Percentages and χ2 Analyses of Sexual and Injection Risk Factor Variables 
 Total  HCV (+) HCV (-) p- 
 N (%)  N (%)  N (%) value 
Sexual Risk Factors 
     
Age at first sexual encounter     
  Less than or equal to 13 98(40.8) 73(40.1) 25(43.1) 0.686 
  14 or older 142(59.2) 109(59.9) 33(56.9)  
  
# of sex partner in past 3 months     
  None or 1 145(60.4) 118(64.8) 27(46.6) 0.013 
  2 or more 95(39.6) 64(35.2) 31(53.4)  
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 Total  HCV (+) HCV (-) p- 
 N (%)  N (%)  N (%) value 
# of sex partners in a lifetime 
  10 or less 50(20.8) 41(22.5) 9(15.5) 0.718 
  11-25 63(26.3) 47(25.8) 16(27.6)  
  26-50 60(25.0) 44(24.2) 16(27.6)  
  More than 50 67(27.9) 50(27.5) 17(29.3)  
     
Injection Risk Factors     
   
Weekly injection frequency     
  Less than everyday 39(16.3) 18(9.9) 21(36.2) 0.000 
  Everyday 201(83.8) 164(90.1) 37(63.8)  
   
Daily injection frequency     
  Less than 4 times a day 111(46.3) 70(38.5) 41(70.7) 0.000 
  4 or more times a day 129(53.8) 112(61.5) 17(29.3)  
   
Use of dirty cooker     
  Half of the time or less 111(46.3) 78(42.9) 33(56.9) 0.062 
  More than half the time 129(53.8) 104(57.1) 25(43.1)  
   
Use of dirty cotton     
  Half of the time or less 140(58.3) 101(55.5) 39(67.2) 0.114 
  More than half the time 100(41.7) 81(44.5) 19(32.8)  
   
Use of dirty rinse water     
  Half of the time or less 149(62.1) 110(60.4) 39(67.2) 0.353 
  More than half the time 91(37.9) 72(39.6) 19(32.8)  
   
Use of a dirty needle     
  Never  103(42.9) 69(37.9) 34(58.6) 0.006 
  Sometimes 137(57.1) 113(62.1) 24(41.4)  
   
IDU’s in personal network     
  25% or less 17(7.1) 13(7.2) 4(6.9) 0.870 
  26% - 50% 28(11.7) 21(11.6) 7(12.1)  
  51% - 75% 26(10.9) 18(9.9) 8(13.8)  
  > 75% 168(70.3) 129(71.3) 39(67.2)  
 
In the sexual and injection risk factor profile (Table 2), weekly injection 
frequency, daily injection frequency, use of a dirty needle and number of sex partners in 
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the past three months were significant at the p = 0.05 level. These analyses suggest that 
the only drug paraphernalia variable that approached significance was “using a dirty 
cooker.” 
 Hypothesis 2 stated that HCV positive individuals will be more likely to engage 
in high-risk sexual behaviors than HCV negative individuals as measured by sexual 
history (age at first sexual encounter) and number of sex partners (number of sex 
partners in last 3 months, number of sex partners in a lifetime). Table 2 indicates that 
40.1% of the HCV positive participants had their first sexual encounter at age 13 or 
younger versus HCV negative participants (43.1%). The outcome was not significant. 
 With regards to number of sex partners in the past three months, it was initially 
analyzed as a continuous variable (mean=6.85, SD=17.77, range=1-100). As a continuous 
variable, number of sex partners in the past three months was not significantly associated 
with HCV infection in the bivariate analyses. The variable was then dichotomized as 
having “none or 1 sex partners” and “2 or more sex partners” and included in the 
univariate analyses. Unadjusted odds (Table 3) indicate that when compared to 
participants that have “none or 1 sex partners”, participants with two or more sex partners 
are significantly less likely to be HCV positive (OR = 0.472, p = 0.014). When 
controlling for all other variables (Table 4), having two or more sexual partners in the 
past three months continued to be a significant protective factor against HCV infection. 
 Given the evidence, it is concluded that HCV positive participants do not differ 
statistically from HCV negative participants in terms of age at first sexual encounter and 
lifetime sexual partners. HCV positive participants do differ significantly from HCV 
negative participants in that participants having two or more sexual partners in the past 
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three months were less likely to be HCV positive when compared to participants that had 
only one sex partner or none in the past three months. 
Table 3 
Unadjusted Odd Ratios for Hepatitis C Infection 
Variable   Percent OR 95% CI p-value 
Demographics 
      
Age      
  18 - 24                    6.7  1.000   
  25 - older                   94.3  4.592 1.627-12-956 0.004 
Gender      
  Female                                    12.5  1.000   
  Male                    87.5  0.592 0.216-1.626 0.309 
Employment      
  Employed 16.7  1.000   
  Unemployed 83.3  0.620 0.258-1.487 0.620 
Income     
  None 39.6  1.000   
  < $5,000 19.2  0.649 0.293-1.434 0.285 
  $5,000 - $9,999 13.8  1.054 0.402-2.767 0.915 
  $10,000 - $14,999 7.9  1.514 0.402-5.694 0.540 
  $15,000 - $19,999 7.1  0.922 0.272-3.127 0.867 
  $20,000 or more 12.5  0.662 0.264-1.660 0.379 
 
 Marital status     
  Married 15.0  1.000   
  Unmarried 85.0  1.381 0.570-3.43 0.474 
 
 Education Level     
  No high school 60.0  1.000   
  High school or GED 40.0  0.769 0.423-1.398 0.389 
 
Hispanic/Latino Ethnic     
Background     
  Mixed Ethnic Background 7.9  1.000   
  Mexican 3.3  4.083 0.412-40.455 0.229 
  Central American 1.7  0.194 0.017-2.248 0.190 
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Variable   Percent OR 95% CI p-value 
  South American 3.3  9.424 0.000-99.00 0.999 
  Puerto Rican 66.7  3.150 1.130-8.781 0.028 
  Cuban 13.8  0.700 0.220-2.226 0.546 
  Dominican 3.3  0.083 0.008-0.826 0.034 
   
Number of years in the U.S. 
  Less than 5 years 45.4  1.000   
  5-10 years 21.7  0.633 0.285-1.409 0.263 
  11-15 years 11.3  0.307 0.123-0.765 0.011 
  16-20 years 8.8  0.422 0.150-1.187 0.102 
  21+ years 12.9  0.607 0.236-1.561 0.300 
 
Born in the U.S     
  Yes/Born in the U.S 83.3  1.000   
  No/Not born in the U.S. 16.7  0.349 0.171-0.713 0.004 
 
Sexual Risk Factors 
     
Age at first sexual encounter     
  Less than or equal to 13 40.8  1.000   
  14 or older 59.2  1.131 0.622-2.058 0.686 
   
# of sex partner in past 3 months     
  None or 1 60.4  1.000   
  2 or more 39.6  0.472 0.260-0.860 0.014 
 
# of sex partners in a lifetime     
  10 or less 20.8  1.000   
  11-25 26.3  0.645 0.258-1.614 0.349 
  26-50 25.0  0.604 0.240-1.516 0.283 
  More than 50 27.9  0.646 0.261-1.160 0.345 
 
Injection Risk Factors 
 
Weekly injection frequency     
  Less than everyday 16.3  1.000   
  Everyday 83.8  5.171 2.508-10.662 0.000 
 
Daily injection frequency     
  Less than 4 times 46.2  1.000   
  4 times or more 53.8  3.856 2.036-7.314 0.000 
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Variable   Percent OR 95% CI p-value 
Use of dirty cooker 
  Half of the time or less 46.2  1.000   
  More than half the time 53.8  1.760 0.969-3.197 0.063 
Use of dirty cotton     
  Half of the time or less 58.3  1.000   
  More than half the time 41.7  1.646 0.884-3.064 0.116 
 
Use of dirty rinse water     
  Half of the time or less 62.1  1.000   
  More than half the time 37.9  1.344 0.720-2.507 0.353 
Use of a dirty needle     
  Never  42.9  1.000   
  Sometimes 57.1  2.320 1.270-4.237 0.006 
 
Use of dirty rinse water     
  Half of the time or less 62.1  1.000   
  More than half the time 37.9  1.344 0.720-2.507 0.353 
   
IDU’s in personal network     
  25% or less 7.1  1.000   
  26% - 50% 11.7  0.923 0.225-3.780 0.911 
  51% - 75% 10.8  0.832 0.414-1.672 0.606 
  > 75% 70.0  1.006 0.680-1.489 0.977 
 
Table 3 shows the unadjusted odds ratios (OR) for HCV infection by independent 
variables. The table shows the percent of the entire sample per categorical value, the 
associated odds ratios as well as the 95% confidence interval (95% CI) and significance 
value. At this step, the significance level of p = 0.20 was utilized to determine variables 
that approached significance and were included in the multivariate model (in Table 4). 
Originally, age (mean=35.8, SD=9.2) was analyzed as a continuous variable 
(range=18-61). When included in the bivariate analyses with all the other variables, it 
was not significant. Age was then dichotomized as “younger age” which is 18-24 years 
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and “older age”, which is 25 years or older. In the bivariate analyses (Table 3), 
dichotomized age was a statistically significant predictor of HCV infection (OR = 4.592, 
p = 0.004).  
Of all of the ethnic groups analyzed, being of Puerto Rican decent was 
significantly associated with HCV infection (OR = 3.150; p = 0.028). This however, 
could be reflective of the fact that there were a large number of Puerto Ricans in the 
study, when compared to all other groups. Both weekly injection frequency (OR = 5.171; 
p = 0.000) and daily injection frequency (OR = 3.856; p = 0.000) were significantly 
associated with HCV status. While not significant at the p = 0.05 level, using a dirty 
cooker (OR = 1.760; p = 0.063) approached significance as a risk factor for HCV 
infection. This finding may suggest that in future studies, with a sample that is more 
representative of the entire population, using a dirty cooker, or any other drug 
paraphernalia may be a significant risk factor for HCV infection among Hispanic/Latino 
IDUs. 
This analysis also uncovered several protective factors for HCV at varying 
significance levels. Being born outside the U.S. (OR = 0.349; p = 0.004) was a significant 
protective factor, along with having two or more sex partners in the past three months 
(OR = 0.472; p = 0.014). Of all the ethnic backgrounds, being of Dominican decent (OR 
= 0.083; p = 0.034) was a significant protective factor for HCV infection. This finding 
however is suspect given the very small number of Dominicans in the study (n=8).  
In order to address the significant factors with regards to “Puerto Rican” and 
“Dominican” ethnic backgrounds, two new variables were created. One variable was 
dichotomized “Puerto Rican/not Puerto Rican” and the other “Dominican/not 
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Dominican”. Upon analyzing both variables in a bivariate model, these new variables 
were no longer significant and were not included in the multivariate model. 
When compared with participants living in the U.S. for less than five years, 
participants who lived in the U.S. between 5-10 years were less likely to be HCV infected 
(although not significant). Participants living in the U.S. between 11-15 years however, 
were significantly less likely to be HCV infected (OR = 0.307; p = 0.011). In addition, as 
time in the U.S. increases, it appears that the protective effects begin to wane; this finding 
was not significant at the p = 0.05 level.  
Hypothesis 1c stated that in comparison with HCV negative individuals, HCV 
positive individuals will be more likely to have resided in the U.S. for a longer period of 
time (number of years in the U.S.) and be born in the U.S. (born in the U.S.). Table 1 
indicates that almost half of HCV positive participants (49.5%) actually have resided in 
the U.S. for less than 5 years. Table 3 shows that the only statistically significant result 
for number of years residing in the U.S. was for the group 11-15 years (p = 0.011), while 
the group 16-20 years approached significance (p = 0.102). The results were not 
significant at any other level. This result may suggest a waning effect as the number of 
years living in the U.S. increases.  
In the unadjusted odds (Table 3), participants born outside the U.S. were 
significantly less likely to be HCV infected (p = 0.004). In the adjusted odds (Table 4), 
being born outside the U.S. continued to be a significant protective factor (AOR = 0.369; 
p = 0.019). These results indicate that HCV positive do differ statistically from HCV 
negative individuals when it comes to living in the U.S. for longer periods of time or 
being born in the U.S. 
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Table 4 (multivariate analyses) includes all variables that were significant at the p 
< 0.20 level in the bivariate analyses. The multivariate analyses show that when 
controlling for all other variables, injecting every day (AOR = 3.238; p = 0.007) as well 
as injecting four or more times per day (OR = 2.265; p = 0.010) were both significant risk 
factors for HCV infection. In addition, age (dichotomized) (AOR = 7.470; p = 0.006) was 
also a significant risk factor for HCV infection when controlling for all other variables. 
Drug paraphernalia variables: using a dirty cooker (AOR = 0.900; p = 0.847); using a 
dirty cotton (AOR = 1.270; p = 0.665); and using a dirty needle at least “sometimes” 
(AOR = 1.882; p = 0.110), were not significant at the p < 0.05 level. 
Table 4 
Adjusted Odd Ratios (AOR) for Hepatitis C Infection 
Variable    Percent AOR 95% CI P-value 
Demographics 
 
Age      
  18 - 24                    5.0  1.000   
  25 - older                   95.0  7.470 1.790-31.170 0.006 
 
Born in the U.S.     
  Yes/Born in the U.S. 83.3  1.000   
  No/Not born the U.S. 16.7  0.369 0.160-0.848 0.019 
 
Sexual Risk Factors 
     
# of sex partner in past 3 months     
  None or 1 32.9  1.000   
  2 or more 39.6  0.481 0.241-0.958 0.037 
 
Injection Risk Factors 
     
Weekly injection frequency     
  Less than everyday 16.3  1.000   
  Everyday 83.8  3.238 1.387-7.560 0.007 
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Variable    Percent AOR 95% CI P-value 
 
Daily injection frequency     
  Less than 4 times 46.2  1.000   
  4 times or more 53.8  2.625 1.258-5.479 0.010 
 
Use of dirty cooker     
  Half of the time or less 46.2  1.000   
  More than half the time 53.8  0.900 0.307-2.639 0.847 
   
 
Use of dirty cotton     
  Half of the time or less 58.3  1.000   
  More than half the time 41.7  1.270 0.431-3.737 0.665 
 
Use of a dirty needle     
  Never  42.9  1.000   
  Sometimes 57.1  1.882 0.867-4.083 0.110 
     
Several protective factors for HCV infection did emerge from this analysis. 
Unexpectedly, having two or more sexual partners in the past three months (AOR = 
0.481; p = 0.037) emerged as a significant protective factor against HCV infection. 
Additionally, being born outside the U.S. (AOR = 0.369; p = 0.019) emerged as a 
protective factor for HCV infection. 
Hypothesis 3a stated that HCV positive individuals will be more likely to engage 
in high-risk injection behaviors than HCV negative individuals, as measured by 
utilization of shared injection paraphernalia (cooker, cotton, rinse water, syringes) and 
injection frequency (weekly injection frequency, daily injection frequency). Table 3 
indicated that participants who injected every day were significantly more likely to be 
HCV positive when compared with participants who injected less than every day. 
Participants who injected four or more times a day were also significantly more likely to 
be HCV infected when compared to participants who injected less than four times a day. 
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With regards to drug paraphernalia, use of a dirty cooker, use of a dirty cotton, and use of 
a dirty needle were all associated with HCV infection. When adjusting for all other 
significant factors (Table 4), weekly injection frequency and daily injection frequency 
were both significantly associated with HCV infection. Use of a dirty needle approached 
significance (p = 0.110), but was not a significant factor in these analyses. 
Based on the evidence, it is concluded that HCV positive participants are 
statistically more likely to engage in riskier injection practices as defined by more 
frequent weekly injections as well as more frequent daily injections. 
Backward regression 
 In order to ensure that the model is stable and does not include too many 
variables, a backward regression was performed using only the variables significant at the  
Table 5 
Backward Logistic Regression of Factors Affecting HCV 
Variable AOR 95% CI P-value 
    
Age 6.918 1.710-27.996 0.007 
    
Born in the U.S. 0.365 0.163-0.816 0.014 
    
Weekly injection frequency 3.737 1.631-8.563 0.002 
    
Daily injection frequency 2.654 1.282-5.496 0.09 
 
p < 0.05 level in the multivariate analysis (variables in Table 4). If any independent 
variable category was significant in the adjusted odds ratios, then it was included in the 
backward logistic regression. The results of the backward regression are included in 
Table 5. 
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The backward stepwise regression showed that age, being born in the U.S., 
weekly injection frequency and daily injection frequency, are all significant variables. 
Number of sex partners in the past 3 months was not significant in the backward logistic 
regression, so it was dropped from the final model. This indicates that introducing this 
variable in the model may make the model somewhat unstable, so care must be taken 
whenever utilizing “number of sex partners in the past 3 months” as a protective factor. 
Summary 
 In summary, this analysis made use of secondary data to determine whether there  
was a significant difference between the HCV positive and HCV negative individuals in 
terms of the demographic profile as well as their sexual and injection risk factors. The 
unadjusted and adjusted odds ratios were used to determine which among the risk factors 
affected the dependent variable. Finally, a backward stepwise regression analysis was 
conducted to determine which among the significant risk factors identified through the 
bivariate odds ratio analysis significantly affected the dependent variable, HCV infection.  
Among all of the studied risk factors, age, being born outside the U.S., weekly 
injection frequency and daily injection frequency were significant factors affecting the 
dependent variable, HCV. 
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CHAPTER V 
DISCUSSION 
 HCV continues to capture the attention of the public health research community. 
For example, the CDC has made May 19th “National Hepatitis Testing Day” and has 
urged all “baby boomers” born between 1945 and 1965 to be tested for HCV, as this 
group represents the age sector with the highest percentage of HCV infection in the U.S. 
(CDC, 2012).  While it is a relatively recent disease, the infectivity rate coupled with its 
correlation with HIV infections due to intravenous drug use continues to keep HCV in the 
spotlight of research (Choo et al., 1989). 
This study is potentially the first that will lay the groundwork for successful 
prevention strategies for intravenous drug users who are currently HCV-negative. While 
it is customary to discuss the results of this study in the context of existing literature, the 
literature is admittedly still in its infancy (Mateu-Gelabert et al., 2007). There are many 
studies that will show associations between behaviors and HCV infection, but an attempt 
at differentiation and quantification of risk factors is still lacking in the literature. 
Moreover, the literature with regards to the varying risk factors of different 
Hispanic/Latino ethnicities is scarce.   
Looking at the overall extant HCV literature however, allows us to compare the 
results of this study with other populations. This study did not find significant 
relationships between HCV and key demographic variables (gender, educational level, 
employment, income, marital status and residency status). This finding (or lack thereof) 
is not supported by national studies, particularly with regard to employment and income. 
According to data from the National Health and Nutrition Examination Survey 
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(NHANES), HCV is more prevalent in subjects who were below the poverty level (Alter 
et al., 1999). In this study, employment and income did not behave as predicted. Being 
unemployed served as a protective factor (not statistically significant), and income was 
inconsistent in its relationship with the odds of having HCV infection. It could be that 
unemployment may serve as a protective factor simply due to economics. Being 
unemployed means that there are no monetary resources to purchase drugs, and in turn, 
inject them (some shooting galleries actually charge an “entrance fee”). A potential 
confounder however is that in lieu of earning money to purchase drugs, a person may turn 
to illegal activities (burglarizing, robbery, etc.). Females (and some males) may turn to 
prostitution, which could help to explain the result found in some studies (discussed later) 
that men are less likely to be HCV infected. With regards to income, no specific pattern 
was obtained from the data, with the possibility of “illegal income” being a potential 
confounder. 
Other demographic variables did behave as predicted, but the results were not 
statistically significant. It was hypothesized that not having a high school diploma/GED, 
being unmarried and living in a hotel/motel/boarding house would all be associated with 
HCV infection. The study results were consistent with those hypotheses, to a limited 
degree, though these results were not borne out in the adjusted analyses. Perhaps a larger 
sample size would assist in determining if indeed those results could potentially be 
significant. 
Age did show a statistically significant relationship with HCV only when 
dichotomized as “younger” and “older”. This could be due to high American 
acculturation in individuals who are in the U.S. for longer periods of time. It has been 
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shown that higher levels of acculturation are associated with an increased likelihood of 
unhealthy behaviors that may have an adverse effect on a person’s health and a decreased 
likelihood of exhibiting health promoting behaviors (Ebin et al., 2001). However, with 
the decline of HCV infection due to blood transfusion in the present day, once a 
significant contributor to HCV infections in the U.S., there may be a potential confounder 
in this relationship (Sy & Jamal, 2006; van den Berg et al., 2007). Still, this potential 
finding is similar to a study linking older age (greater than 35) to an increased probability 
of HCV infection (Spradling et al., 2010). 
Another important finding was that being born outside the U.S. is a potential 
protective factor when compared to being born in the U.S. While the HCV literature is 
lacking in this form of investigation, the HIV literature has examined the effects of place 
of birth and health (Delgado, Lundgren, Deshpande, Lonsdale, & Purington, 2008). 
Country of birth (U.S./non-U.S.) was significant in all analyses. This finding hints at the 
possibility that recently arrived immigrants may be healthier than Hispanics/Latinos who 
have been in the U.S. for a longer period of time (consistent with the “Hispanic paradox” 
theory). According to several studies, the longer Latinos stay in the U.S., the less healthy 
they generally become, with American acculturation associated with poorer health 
(Delgado et al., 2008; Lara, Gamboa, Kahrramanian, Morales, & Bautista, 2005).   
The finding that being born outside of the U.S. could be a potential protective 
factor is consistent with studies that have shown that U.S. immigrants have better health 
outcomes than U.S.-born Americans in chronic noninfectious disease (Singh & Hiatt, 
2006; Wei, Valdez, Mitchell, Haffner, Stern, & Hazuda, 1996). Unfortunately, HCV is an 
infectious disease and immigrants do not have the advantage in all diseases. For example, 
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a majority of recent U.S. immigrants are from the third world where the incidence and 
prevalence of many infectious diseases are higher than in the United States. For example, 
of all the tuberculosis cases diagnosed in the U.S. in 1999, 43% were from foreign born 
immigrants (CDC, 2001). Both hepatitis A and hepatitis B infections are more common 
in immigrants than in U.S.-born individuals (McQuillan, Coleman, Kruszon-Moran, 
Moyer, Lambert, & Margolis, 1999; Wasley et al., 2007). In addition, foreign-born 
Americans have been reported to be associated with a high risk of H. pylori seropositivity 
and Toxoplasma gondii infection (Everhart, Kruszon-Moran, Perez-Perez, Tralka, & 
McQuillan, 2000; Jones, Kruszon-Moran, Wilson, McQuillan,Navin, & McAuley, 2001). 
Along with this, the results of the present study show that participants living in the U.S. 
for 5-15 years have lower odds of being infected by HCV when compared to those living 
in the U.S. for less than 5 years; however, beginning in the 16th year (unadjusted odds) 
and after the 21st year (adjusted odds) the odds of infection increase. While these results 
are not statistically significant, it hints at the possibility that there may be some sort of 
dose-response relationship between number of years living in the U.S. (or possibly 
American acculturation, which can be hypothesized to increase the longer a person lives 
in the U.S.) and HCV infection. The “healthy immigrant” effect coupled with a higher 
incidence of infectious diseases in third world countries could essentially be cancelling 
each other out and possibly causing non-significant results when adjusting for other 
variables in the study. 
When compared to females, males tended to be less likely to have HCV infection. 
This finding is contrary to what was hypothesized. Given the sheer gender difference in 
the sample (males accounted for 87.5% of the sample) it was assumed that statistically, 
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males would be associated with HCV infection, even if not statistically significant. This 
finding suggests the possibility that if the sample were equal in terms of gender, perhaps 
a significant result would be obtained. A suggestion for further research would be to 
oversample females in order to obtain a more equitable distribution and then analyze the 
results. 
Many studies indicate that injection drug use is the main mode of HCV 
transmission (Rustgi, 2007). There is a need for the scientific community to understand 
what risk factors are shared between different Hispanic/Latino groups and the generally 
well-studied Caucasian, non-Hispanic/Latino population. Once the scientific community 
understands what risks are shared, then research can focus on what is different between 
not only Caucasians (Non-Hspanic/Latino) and Hispanics/Latinos, but what are the 
different risk factors within the Hispanic/Latino ethnicity. For example, while overall 
injection drug use is a risk factor for HCV infection, the risk may be differential 
depending on the race-ethnicity of the participant. For example, in some studies, Asian 
patients had a negligible risk of HCV related to IDU versus a very prevalent exposure in 
Hispanics/Latinos and African Americans (Celona et al, 2004). Unfortunately, this study 
did not have a large enough sample of other Hispanic/Latino populations in order to 
stratify analyses and examine HCV risk associated with injection behavior by different 
nationalities. Further studies should seek to perform those stratified analyses and attempt 
to ascertain if there are different risks by different Hispanic/Latino nationalities. Knowing 
this would help researchers design and tailor interventions to different groups depending 
on their risk level. 
 62
While the present study did show a positive association between injection 
frequency and HCV infection, knowledge of the infectivity rate of HCV informs the 
healthcare community that just one infected needle will be enough to infect the user. 
Given the high prevalence of HCV in the IDU community, every time a dirty needle or 
any paraphernalia is re-used, there is a very high probability of being infected with the 
HCV virus. While not significant in the adjusted odds ratios, use of a dirty cooker 
approached significance and should be studied further as a possible risk factor for HCV 
infection. This finding should be explored further as it has been shown that drug 
paraphernalia, particularly cookers, can transmit the HCV virus (Hagan et al., 2001). 
An unexpected finding of this study was that having two or more sex partners in 
the past three months was negatively associated with HCV infection. Having more sex 
partners was not expected to act as a protective factor. To date, there is no known study 
that confirms this finding. One explanation for this may be that a participant with more 
sexual partners may be more likely to use barrier protection when compared with a 
participant with fewer sexual partners. The individual still may become infected through 
their injection behavior, therefore that sexual/injection behavior dynamic should be 
explored further. This particular study did not address condom use in this population, 
therefore a suggestion for further research would be to more closely examine the sexual 
habits of IDUs and determine if their infection status may lead to protective behaviors in 
certain areas, such as their needle sharing behaviors. Care must be taken when 
referencing this finding however, because this variable was not significant in the 
backward regression model, meaning that it could be a potential confounder. Further 
research is necessary in order to solidify this finding. 
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The debate with respect to the sexual transmission of HCV continues with 
evidence on both sides of the issue. Currently, the CDC considers HCV infection from 
sexual contact to be extremely low, and some may say that the evidence for HCV 
infection due to sexual contact is weak (CDC, 2008; Alary et al., 2005). Again, the 
literature is quite sparse in this area, possibly because of the CDC’s determination. There 
is however, a rapidly growing body of literature, particularly focusing on the MSM 
population that is currently investigating sexual contact as a single risk factor for HCV. 
Study limitations 
 Several study limitations are noted. First, the cross-sectional design of the original 
study did not allow a determination of whether HCV infection occurred before or after 
any injection behavior. True quantification of sex partner relationships and injection 
frequency could also not be known with certainty due to the original study’s reliance on 
self-report and retrospective data. Given the selection criteria for the study (current IDUs, 
Hispanic/Latino origin), and the location of the study (Miami, FL), these findings cannot 
be generalized to other groups of IDUs or other cities in the U.S. Other limitations to this 
study include a small sample size (a larger sample would provide more power, adding to 
the significance of the results), lack of female participants in the study, as well as low 
numbers of participants from the ethnicities besides Puerto Ricans. In addition, the 
snowball sampling technique does not ensure that the sample is a representative sample 
of all Hispanic/Latino IDUs in Miami-Dade County, FL. 
Suggestions for further research 
 As mentioned before, further research in this area should concentrate on the 
sexual habits of the IDUs and determination as to whether their sexual habits change due 
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to their HCV status. Additionally, there are no definitive studies that either support or 
refute sexual activity as a risk factor for HCV. Further research should determine exactly 
how much of a risk factor sexual activity presents. This type of research would allow a 
determination about whether to continue studying the behavior or refocus efforts on 
intravenous drug use.  
Another suggestion for further research is to expand the current sample in order to 
ensure that there are large enough groups of participants that were underrepresented in 
the current study. For example, a future sample would include more women as well as 
more people who identify themselves as being of Hispanic/Latino ethnicity and are from 
groups that did not have large numbers in this sample (Mexican, Central Americans, 
South Americans and Dominicans). Given that targeted, individual-level HCV prevention 
strategies are still needed, there is a need to move from the theoretical realm and into the 
applied world, develop comprehensive prevention programs for HCV-negative IDUs and 
harm reduction programs for HCV-positive IDUs, and evaluate and refocus those 
programs for maximum efficiency (Birkhead et al., 2007; Herbst et al., 2007; Edlin & 
Carden, 2006). 
Lastly, little research has been done on the effectiveness of interventions such as 
syringe exchange and harm reduction techniques associated with drug use paraphernalia 
in HCV-positive samples. To determine the effectiveness of such interventions, 
epidemiologic research would be invaluable. Research into the impact of care and 
treatment, in light of recent advancements should also be conducted. 
 The framework for HCV education exists today. Given that HIV and HCV follow 
the same trajectories in terms of epidemiology and routes of infection, HCV education 
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can be incorporated into current HIV educational programs. It is important to note that 
while the HCV education program could be incorporated into extant HIV programs, 
actual interventions against both infections may not be the same. As suggested by Mateu-
Gelabert and colleagues (2007), the current HIV interventions retooled for HCV are 
practically non-existent and those that do exist are simply not working. Educational 
programs must first be instituted (with the help of current HIV education programs), but 
interventions must be created from the ground up in order to meet the challenges 
presented by HCV infection. This is especially important when designing interventions 
that are culturally tailored to the different Hispanic/Latino groups in the U.S. For 
example, HCV interventions should focus on IDUs, particularly the reduction in number 
of exposures by the user. This could potentially be coupled with a needle exchange 
program (even in light of the political obstacles to that approach). In addition, the 
reduction in exposure (injection frequency) will likely be achieved via a standard IDU 
prevention program but would be limited by the success of these types of programs. 
It has been suggested that prevention programs reassess and refocus their efforts 
and improve their targeting, selection, and delivery of their prevention messages 
(Bertozzi, Laga, Bautista-Arredondo, & Coutinho, 2008). It is now time to do just that 
(re-assess, refocus, and target prevention programs), and strive for more efficiency in 
delivering these messages. This effort requires better understanding of the intricate 
dynamics and differences among IDUs, and the differences in their behaviors with 
regards to their ethnic background. Knowing these differences and targeting them will 
lead to better prevention programs. 
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Conclusions 
The burden of HCV on the Hispanic/Latino population is high. It is entirely 
possible that even with all that is known in this area, not all HCV cases are reported, 
suggesting that prevalence and incidence rates may be even higher than reported. These 
realizations lend credence to HCV’s unofficial title of “the silent epidemic” (Edlin, 2011; 
Mitchell, Colvin, & Palmer, 2010). HCV suffers from several issues that impede 
researchers. First, its asymptomatic nature does not seem to cause enough “urgency” in 
the population. More importantly, HCV simply does not benefit from the advocacy 
enjoyed by other diseases, such as HIV (Edlin & Carden, 2006; USDHHS, 2001). For 
example, in 2006, world governments committed themselves to scaling up HIV 
prevention and treatment responses (UNAIDS, 2007). Even so, while treatment access 
has expanded rapidly, the number of new HIV infections has not decreased (UNAIDS, 
2007). HCV is going to need a commitment of that magnitude, and perhaps even larger, 
in order to reduce incidence and prevalence rates in the population. Resources are needed 
to strengthen and standardize the current infrastructure to best support identified and 
unknown infected cases. National funding should be increased so that new cases are 
prevented, and existing cases are identified and linked to care. The latter would prevent 
secondary transmission and disease progression to advanced stages, essentially saving 
healthcare dollars. 
In conclusion, current research into HCV, its transmission routes, and effective, 
culturally adapted interventions aimed at reducing its impact on the Hispanic/Latino 
population is just beginning. The breadth of research required to fully understand the 
HCV epidemic will continue to be uncovered as more information emerges. This study is 
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one of hopefully many others that will add to the current body of knowledge that can be 
used to inform health policy and planning decisions regarding identification of risks, 
effective interventions and resource allocation. 
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CHAPTER VI 
PROPOSAL OF A TARGETED, THEORETICALLY-BASED HCV PREVENTION 
INTERVENTION 
There have been a few attempts at primary prevention of HCV within at-risk 
populations. In the past 20 years, only 18 studies have been identified that are 
interventional in nature and describe a primary prevention intervention targeting IDUs 
and aiming to reduce the incidence of HCV (Wright & Tompkins, 2006). Of the 18 
studies identified in this time period, only four studies were conducted in the U.S. that 
included or possibly included Hispanics/Latinos (Hagan et al., 1999; Hagan, Des Jarlais, 
Friedman, Purchase, & Alter, 1995; Kapadia et al., 2002; Thiede, Hagan, & Murrill, 
2000). 
For the purposes of developing a targeted intervention aimed at reducing HCV 
infection in the Hispanic/Latino IDU population, individual risk factors that were found 
to be significantly associated with HCV infection will be targeted for behavioral 
intervention. The intervention will be tailored around 1) assessing the individual’s 
readiness to change the selected behavior via an algorithm developed by Cabral et al. 
(2004), and 2) systematic activities aimed at moving individuals from one stage of 
change to another, with established outcomes needed to successfully move to each 
successive stage. 
Given the results of the study, targeting IDUs who inject every day of the week 
would be the ideal group to target for this HCV prevention intervention. The following is 
a proposal for a targeted intervention that will attempt to change the injecting behaviors 
of the target population. In this particular case, the target behavior would be to reduce the 
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weekly injection frequency to a target of a maximum of three times a week versus every 
day of the week. 
Intervention Development 
 There have been several studies that have looked at the TTM as an effective 
model for behavior change in IDU’s (Appel, Ellison, Jansky, & Oldak, 2004; Booth et al., 
1996; Booth et al., 1998; Neff & Zule, 2000, 2002). In addition, the TTM served as the 
basis for CDC’s AIDS Community Demonstration Project, which is “A Successful 
Community-Level Intervention to Reduce HIV Risk” (CDC, 2007). There is also an 
abundance of research that has examined readiness to change as factors in substance 
abuse treatment retention and outcomes (Annis et al., 1996; Avants, Margolin, & Kosten, 
1996; Carboni & DiClemente, 2000; Connors et al., 2001; DiClemente & Hughes, 1990; 
Goldbeck, Myatt, & Aitchison, 1997; Gwaltney et al., 2001; Longabaugh & Wirts, 2001; 
Maisto, Carey, & Bradizza, 1999; Prochaska & DiClemente, 1983; Prochaska, Velicier, 
DiClemente, & Fava, 1988; Ramsey et al., 2000; Reilly et al., 1995). No research was 
found however that covers Hispanic/Latino IDUs specifically. However, the supporting 
evidence shows that the TTM methodology is an effective intervention for this group 
(IDU’s), and the TTM’s flexibility allows it to incorporate cultural elements that may 
lead to better outcomes in drug treatment programs (Warner et al., 2006).   
 This proposed TTM intervention for Hispanic/Latino IDUs would focus on 
participants who report injecting at least once a day. The first step of the intervention 
would be to identify and recruit participants for the program. Trained community 
outreach workers, along with peer educators would disseminate materials advertising the 
intervention in the community. Potential participants would have the option of 
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anonymously contacting the project staff in order to request more information about the 
program. In addition, the program would benefit from a website where participants can 
learn more about the program as well as HCV infection.  The website would also feature 
a simple algorithm aimed at assessing a participant’s willingness to reduce their injection 
frequency to at least three times per week. The website will have an option for the 
potential participant to leave contact information and program staff may contact that 
participant at a later time or through real time chat sessions or personal contact. The use 
of the internet has been somewhat successful in providing information and surveying 
drug addicts, mainly methamphetamine users (Recovery and Treatment of Crystal Meth, 
2012) as well as those with chronic diseases, and substance abuse problems such as 
nicotine and alcohol addiction (Copeland & Martin, 2004). It is theorized that the 
internet’s interactivity, flexibility, relative availability and most of all, confidentiality will 
allow users to be more forthcoming, improving the reliability of responses (Copeland & 
Martin, 2004; Miller & Sønderlund, 2010). Participants who are not ready to be in an 
intervention can be redirected to a general informational site about drug use and HCV. 
Another proposed outreach technique would be to arrive at a specific location 
every day at the same time in order to create awareness and an expectation by the 
potential participants. Finally, it would be important that the community outreach 
workers be as diverse as the population served, hence it would be important that the 
worker be of the same Hispanic/Latino background (preferably same country of origin) as 
the participants in the intervention.  
Participants eligible for the program would include any IDU over the age of 18 
who injects every day of the week. HCV seroprevalence will not be a factor in 
 71
 
Question 1 
 
Answer 1 
 
Question 2 
 
 
Answer 2 
 
 
 
Question 3 
 
 
Answer 3 
 
 
Stage 
Figure 1. Algorithm for stage of change assessment. Adapted from Cabral et al. 2004. 
 
determining whether a person may participate in the program. All interviews would 
normally be done in a group format, as it will be the most financially feasible format. 
In a typical week, how often do you inject 3 or less times a week? 
All the time Sometimes or almost 
every time Almost never or never 
How long has it 
been since you 
inject 3 or less times 
a week? 
In the next 6 months, 
how likely are you to 
inject 3 or less times a 
week? 
More than 6 
months 
6 months or 
less 
In the next 6 months, 
how likely are you to 
inject 3 or less times a 
week? 
Very likely 
Not likely/Not 
sure 
Very Likely 
Not likely/Not sure 
In the next 30 days, how 
likely are you to inject 3 or 
less times a week? 
Not likely/Not 
sure 
Maintenance Action Preparation Contemplation Precontemplation 
Very Likely 
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There is however, room for individualized consultations should it be deemed necessary 
by the counselors. 
The next step in the intervention program would be to assess the stage of 
readiness for change in each potential participant. Utilizing an algorithm developed by 
Cabral et al. (2004), the participant’s current stage of readiness may be determined by 
asking a series of questions. Depending on the answers given by the participant, the stage 
of readiness will be determined (See Figure 1). 
There are three main staging questions that can be utilized to determine the 
participant’s stage of change. The first question is “In a typical week, how often do you 
inject three or less times a week?” The second question is “How long has it been since 
you injected three or less times week?” OR (depending on the answer), “in the next 6 
months, how likely are you to inject three or less times week?” Finally, a third question 
will differentiate between participants in the “preparation” or “action” stages. These 
questions could be asked as part of a focus group or as part of a one-on-one interview. 
Once it is known in what stage the participant is in, then the tailored intervention 
can begin. Figure 2 shows all the different stages, their definition as it pertains to this 
intervention, the activities aimed at moving the individual from that particular stage and 
the minimum desired outcome. 
Precontemplation Stage 
Participants in this stage either have no intention of injecting three times or less in 
the next six months or are unaware that there is a problem with their behavior. Given that 
cognitive and emotional processes facilitate movement in these stages (Cabral et al., 
2004), activities in this stage will be aimed at raising consciousness and self-reevaluation.  
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  Precontemplation     Contemplation       Preparation            Action      Maintenance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Intervention design for Hispanic/Latino IDUs 
These interviews and education are aimed at clarifying with participants that it is 
their responsibility to make the decision about behavior change. A technique employed 
during interviews will be to identify and evaluate the pros and cons of their current 
behavior; the same process will be used for the behavior change. In addition, the 
participant is encouraged to identify and promote new and positive outcome expectations. 
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Overall, the purpose of these activities is raise awareness in the individual about 
their behavior. Once the individual is aware that their unhealthy behavior may be directly 
related to their health status, it is hypothesized that they may be ready to enter into 
another stage of readiness. 
This process is designed to occur over 60 days maximum, at which time the 
participant will be once again assessed as to in which stage of change they currently find 
themselves. If the stage has not changed, individualized counseling sessions will be 
scheduled in order to more thoroughly raise the participant’s awareness about HCV. If 
the stage has changed, then the individual will progress to the appropriate category. 
Successful movement by the participant from this category into the next category entails 
a solid commitment to reduce injection frequency in the next six months. 
Contemplation Stage 
Participants in the contemplation stage recognize the need for behavior change 
but either lack motivation or lack the skills necessary for action. In this stage, it is 
important to let the participant know that the decision to inject less frequently (three or 
less times a week) is theirs alone.  
An effective tool that could be used at this stage is an HCV knowledge and 
attitudes questionnaire. While to date there are no valid and tested questionnaires that 
assess HCV knowledge among Hispanic/Latino groups, there are several baseline 
questions that may be asked (Evans, 2005). The HCV knowledge and attitudes 
questionnaire will be used as a gauge to determine if the participant is ready to move on 
to the next stage. It is very important to have a valid and reliable tool at this stage (as well 
as the preparation stage) because it is important that participants are not prematurely 
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moved to later stages of the program because the relapse rate may increase dramatically 
(MacMaster, 2004).  
A good model for an HCV knowledge questionnaire (HCVKQ) could potentially 
be developed from the HIV Knowledge Questionnaire (HIVKQ) developed by Carey and 
Schroeder (2002). This is a brief (18 item) questionnaire that assesses a participant’s HIV 
knowledge level. Higher scores (16-18) indicate a proficient understanding of HIV-
related knowledge (Carey & Shroeder, 2002). An HCV knowledge questionnaire should 
be developed and would be a useful tool for this intervention. Attitude questionnaires 
have been successfully used for HCV behavioral interventions and could be combined 
with an HCV knowledge questionnaire and adapted for this population (Eassa et al., 
2007). 
Focus groups will also be utilized to obtain more thorough information about the 
participants’ HCV knowledge. Utilizing the topics from the focus group, the counselor 
could lead informational sessions that target the participants concerns and educates them 
about HCV. 
In addition to administering the HCVKQ, continuing educational sessions would 
be administered. These sessions are aimed at continuing to increase awareness and 
knowledge about HCV and the need to reduce injection frequency to three times or less 
per week. Motivational interviewing would also be utilized as one of the techniques that 
will move participants into the next stage. In addition, one-on-one interviews may be 
conducted in order to assess any potential barriers that may prevent the reduction of 
weekly injection frequency. During these sessions, techniques for overcoming these 
barriers will be discussed and practiced. 
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After a period of 60 days, the participant will once again be assessed for their 
current state of readiness. If participants remain in the current stage, then more 
individualized attention will be given to them in order to determine the barriers to 
change. If the participant regresses, then they will receive individualized attention in 
order to prevent further relapse. If the participant progresses, then they will move to the 
next stage of readiness. Successful movement by the participant from this category into 
the next category entails a solid commitment to reduce injection frequency in the next 30 
days. 
Preparation Stage 
Individuals in this stage may need new skills for making change. Participants may 
have had some experience with behavior change and are generally “testing the waters.” 
At this stage, it is important that the individual practices the desired behavior. Given this, 
role playing activities and negotiating skills will be the primary foci of this stage. The 
participant will be expected to identify obstacles and/or assist in problem solving. During 
this stage, the participant may also be required to identify and access social support. 
Participants in this stage will also be shown that they may have underlying skills 
for behavior change. Through role playing and constant practice scenarios, the participant 
will be encouraged to take small steps to increase the desired behavior. This stage may be 
one that takes the longest, therefore assessment of the stage will occur monthly for three 
months in order to ensure that the behavior is being performed consistently. 
If the participant regresses to a lower stage, individualized counseling along with 
more contact with peer educators will be conducted. If the behavior is found to be 
consistent over a period of three months, then counseling will continue until six months, 
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at which time the participant will once again be restaged. If the participant is found to 
have progressed and has maintained the healthy behavior for six months, the participant 
will progress to the next stage. Successful movement by the participant from this 
category into the next category entails attempting to reduce injection frequency to three 
times or less per week for at least six months. 
Action Stage 
Individuals in this stage have been practicing their behavior for less than six 
months. During this stage, it is important to continue reinforcing the desired behavior in 
order to avoid relapse. It is during this stage that role playing is done more frequently, 
with the participant assuming not only the roles of the person attempting to reduce their 
injection frequency, but also the person pressuring or avoiding reduction of weekly 
injection frequency. In addition, participants in the later stage can train to become peer 
educators. As a peer educator, they will be trained in the TTM, will learn to assess 
participants on their stage of readiness, and recruit participants into the program. 
Additionally, participants in this stage will learn stimulus control as part of their 
maintenance of healthy behaviors. At the end of three months, the participants will be 
assessed again. If they have relapsed, then more in-depth counseling will be performed. 
Specific “triggers” will be identified and coping strategies will be discussed in order to 
avoid further relapse. Participants who progress will be moved to the final stage. 
Participants who do not progress will remain in this stage with more individualized 
counseling. Successful movement by the participant from this category into the next 
category entails reduction of injection frequency to three times or less per week for six 
months or more. 
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Maintenance Stage 
Individuals in this stage have been consistently performing the desired behavior 
for no less than six months consecutively. It is during this stage that participants make a 
commitment to program staff to continue the behavior for at least one year. Participants 
in this stage learn to focus on restructuring cues and to access social support whenever 
needed. During this stage as well, participants are taught to “reward themselves in 
healthy ways” and make those rewards reinforce their healthy behavior. During this 
stage, participants are also taught to deal with possible relapse and how to cope with that 
scenario. 
Participants in this stage also have the option of becoming peer educators as well 
as outreach workers, will also be able to teach negotiation skills to other participants, and 
recruit participants. All of these activities are aimed at suppressing any triggers and 
continue the healthy behavior. Successful movement by the participant from this category 
into the next category entails successfully reducing injection frequency to three times or 
less per week for at least 12 months. 
Relapse 
Relapse is a concept that is dealt with early in the program in hopes of averting it 
completely. It is expected that a significant percentage of the participants will relapse to 
their unhealthy behaviors (in this case, more frequent injecting). A majority, up to 90% of 
IDUs who seek drug counseling services, are not in the action stage (MacMaster, 2004).   
If an individual experiences a relapse, the first thing that should be done is to evaluate the 
“trigger.” Once identified, it would be easier for the participant to identify that particular 
trigger in future situations and be able to cope accordingly. At this point, peer educators 
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and case workers will work with the participant in order to reassess their motivation and 
identify any barriers they may be experiencing. Stronger coping strategies will also be 
discussed. At the end of each cycle, participants will be restaged in order to make sure 
they are not relapsing. If they are relapsing, then appropriate and more aggressive 
measures will be taken in order to have participants stay in the program. Another reason 
for restaging after every stage is that risk behaviors are dynamically interacting with each 
other, and IDUs may circle between stages of behavior change several times before 
achieving a successful change (Prochaska and Velicer, 1997). 
Discussion 
Prochaska and DiClemente (1982) categorized change processes into verbal 
(cognitive-affective) and behavioral, indicating that each set of strategies were more 
appropriate during certain stages of the model. These processes of change were defined 
as the strategies that assist the change process and include consciousness raising, self-
reevaluation, self-liberation, counterconditioning, stimulus control, reinforcement 
management, helping relationships, dramatic relief, environmental reevaluation, and 
social liberation (Petrocelli, 2002; Prochaska & DiClemente, 1982). Each change process 
is thought to elicit a specific change behavior, thus initiating the movement to the next 
stage, as outlined in the TTM (Petrocelli, 2002). 
Studies show that behavior change is a gradual process (Cabral et al., 2004). 
Cabral (2004) measured effects for two years after an intervention, and cautioned that 
sustained intervention may be necessary past that time. In addition, several techniques 
have been identified that make this intervention work: use of theory; integration of 
programs in the community; use of culturally adjusted role model stories and counseling 
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activities; use of peers as educators and outreach workers; repetition of the messages 
through multiple outlets; and multiple contacts with project staff have been identified as 
markers for success in a program such as this one (Cabral et al., 2004). 
In addition, it is imperative that a program evaluation be conducted to ensure that 
the intervention is doing what it was designed to do. In order to achieve this, data should 
be collected as part of the program. When participants enter the program, their current 
state of readiness could be recorded. After a period of three years, when enough time has 
passed to allow for several cohorts to complete the program, participants could be re-
assessed as to their current state of readiness reduce their weekly injection frequency. A 
significant positive result would be the finding that more people in the sample are at later 
stages of readiness compared to the baseline.  
If the program does not produce desired results, then it will be reworked, with 
input from the community to assess where the program is failing and how more 
individuals could be moved into a maintenance stage of less frequent weekly injection. 
Finally, this progran could be one of many, for example with a second program aimed at 
reducing injection frequency to just once a week and eventually no injections at all. 
Possible barriers 
While the advantages of this program have been discussed as well as the 
theoretical framework utilized, there are admittedly several drawbacks. First, no single 
theoretical model can account for the diversity in behavior. However, reviews of journal 
articles published in the past two decades across a broad range of health behavior topics 
have revealed that along with the Health Belief Model (HBM) and the Theory of  
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Reasoned Action (TRA), the TTM is a popular and effective theoretical framework to use 
in many cases (Glanz & Bishop, 2010).  
Second, moving individuals from one stage of change to another may take a long 
time. Individuals may drop out or move, leading to loss of the program’s ability to 
conduct follow-up. Loss to follow-up may potentially be a significant challenge in this 
program, since most of the intervention consists of repeat visits to seminars and focus 
groups. Since the program will be tailored to different Hispanic/Latino nationalities, there 
must be a cultural component included. Unfortunately, the cultural component will be as 
varied as the different nationalities. This variety will not be known until there is a pilot 
phase and it is understood what type of cultural component works best with the selected 
population. There also is no “brief” version of the program, and HCV educators must be 
aggressive in getting participants to stay for the entire length of the program. Finally, to 
date there is no comprehensive HCV knowledge questionnaire that could serve as a 
measure for assessing baseline knowledge of HCV by potential participants. 
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APPENDIX 1 
 
Selected items from The Modified AIDS Risk Behavior Questionnaire 
 
1. What is your date of birth?     
2. That makes you how old?      
3. Gender of Respondent 
-Male 
-Female 
4. Where were you born?      
5. How many years have you lived in the U.S.?     
6. Do you consider yourself to be Hispanic or Latino? 
-Yes 
-No 
-Refuse to answer 
7. Which of the following best describes your ethnic background? Please check all that 
apply. 
-Mexican 
-Central American 
-South American 
-Puerto Rican 
-Cuban 
-Dominican 
-Spaniard, from Spain 
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-Refuse to Answer 
8. What is the highest level of education you have completed?  (Choose one) 
-8th grade or less 
-Some high school (9th to 11th grade) 
-High school graduate (12th grade) or GED 
-Some college or technical training 
-College graduate or higher 
-Refuse to Answer 
9. What was your total household income from all legal sources last year? (Choose one) 
-Less than $5,000 
-$5,000 - $9,999 
-$10,000 - $14,999 
-$15,000 - $19,999 
-$20,000 - $24,999 
-$25,000 - $29,999 
-$30,000 - $34,999 
-$35,000 and above 
10. Which one of the following best describes your work situation in the LAST 3 
months? (Choose one) 
-Regular full-time work (30 or more hours a week) 
-Regular part-time work (Less than 30 hours a week) 
-Labor pool work 
-Occasional work (daily) 
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-Unemployed (actively seeking for a job) 
-Retired 
-Unable to work – disabled 
-Homemaker 
-Student 
-Other: (Specify)_____________ 
11. What is your current marital situation? (Choose one) 
-Single 
-Officially married 
-Divorced 
-Widowed 
-Refuse to answer 
12. Where were you living during most of this 3 month period? (check all that apply) 
-Your house or apartment 
-Spouse's house or apartment (if you do not consider this your own home) 
-Girlfriend/boyfriend's house or apartment 
-Parent's house or apartment 
-Other relative's house or apartment 
-Friend's house or apartment (not a sex partner) 
-A hotel 
-A rooming or boarding house 
-A halfway house 
-A shelter 
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-A welfare boarding home 
-Abandoned building 
-On the streets (a vacant lot, park, car) 
-Jail/prison 
-Some other place I haven't mentioned (SPECIFY)    
13. In a typical week that you inject drugs, how many days do you inject at least once a 
day?  (Choose one) 
-1 day per week 
-2 days per week 
-3 days per week 
-4 days per week 
-5 days per week 
-6 days per week 
-7 Everyday 
14. On the days that you inject, how many times do you inject?    
15. Of the times you injected in the past 3 months, how often did you inject using a 
needle or syringe that had been used by somebody else to inject? (Choose one) 
-Always 
-Almost Always 
-More than half the time 
-About half the time 
-Less than half the time 
-Rarely 
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-Never 
-Refuse to Answer 
16. Of the times you injected in the last 3 months, how often did you use a cooker with 
someone or after someone else used it?  (Choose one) 
-Always 
 -Almost Always 
 -More than half the time 
 -About half the time 
 -Less than half the time 
 -Rarely 
 -Never 
-Refuse to Answer 
17. Of the times you injected in the last 3 months, how often did you use cotton at the 
same time or after another person used it?  (Choose one) 
-Always 
-Almost Always 
-More than half the time 
-About half the time 
-Less than half the time 
-Rarely 
-Never 
-Refuse to Answer 
18. Of the times you injected in the last 3 months, how often did you use rinse water with 
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or after another person drew up water or rinsed their syringe in it?  (Choose one) 
-Always 
-Almost Always 
-More than half the time 
-About half the time 
-Less than half the time 
-Rarely 
-Never 
-Refuse to Answer 
19. How old were you when you first had sex?    
20. Since you became sexually active, how many different sex partners have you had?  
   
21. How many different sex partners did you have in the last 3 months?    
22. Of the people you currently know, how many inject drugs? (Choose one) 
-None 
-A few 
-About 25% 
-About half 
-About 75% 
-Almost all 
-All 
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